[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1842
1. Staudacher C, Di Palo S, Tamburini AM, Vignali A, Orsenigo E: [The role of neoadjuvant radio-chemotherapy in the treatment of rectal cancer]. Ann Ital Chir; 2007 Nov-Dec;78(6):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Il ruolo della radiochemioterapia neoadiuvante nel trattamento del tumore del retto.
  • PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end.
  • Five-years overall survival and disease-fee-survival were respectively 73% and 60%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Neoadjuvant Therapy / methods. Radiotherapy, Adjuvant. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Rectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510028.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Rennel E, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D, Harper S: The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer; 2008 Apr 08;98(7):1250-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice.
  • Vascular endothelial growth factor-A is widely regarded as the principal stimulator of angiogenesis required for tumour growth.
  • The most studied isoforms, VEGF165 and VEGF165b have been shown to be present in tumour and normal tissues respectively.
  • Here we show that overexpression of VEGF165b by tumour cells inhibits the growth of prostate carcinoma, Ewing's sarcoma and renal cell carcinoma in xenografted mouse tumour models.
  • Moreover, VEGF165b overexpression inhibited tumour cell-mediated migration and proliferation of endothelial cells.
  • These data show that overexpression of VEGF165b can inhibit growth of multiple tumour types in vivo indicating that VEGF165b has potential as an anti-angiogenic, anti-tumour strategy in a number of different tumour types, either by control of VEGF165b expression by regulation of splicing, overexpression of VEGF165b, or therapeutic delivery of VEGF165b to tumours.
  • [MeSH-major] Neoplasms / pathology. Vascular Endothelial Growth Factor A / pharmacology
  • [MeSH-minor] Alternative Splicing. Animals. Carcinoma, Renal Cell / pathology. Cell Movement / drug effects. Cell Proliferation / drug effects. Down-Regulation. Endothelial Cells / drug effects. Male. Mice. Mice, Nude. Neoplasm Transplantation. Neovascularization, Pathologic. Prostate / cytology. Prostate / drug effects. Prostatic Neoplasms / pathology. Protein Isoforms. Sarcoma, Ewing / pathology. Transfection

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2007 Mar;18(3):719-29 [17267748.001]
  • [Cites] Cell Mol Life Sci. 2006 Sep;63(17):2067-77 [16909199.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):223-30 [17595666.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5808-15 [17353901.001]
  • [Cites] Biomed Pharmacother. 2008 Mar;62(3):158-63 [17851027.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):768-76 [10842189.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4123-31 [12124351.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4 [12516033.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):843-5 [1279431.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4575-80 [7553632.001]
  • [Cites] J Urol. 1997 Jun;157(6):2323-8 [9146664.001]
  • [Cites] J Urol. 1997 Jun;157(6):2329-33 [9146665.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7647-54 [15520162.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7822-35 [15520188.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2805-16 [15625332.001]
  • [Cites] Oncogene. 2005 Jan 27;24(5):889-901 [15580293.001]
  • [Cites] Diabetologia. 2005 Nov;48(11):2422-7 [16193288.001]
  • [Cites] Urology. 2006 Aug;68(2):244-8 [16904427.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):133-42 [17027147.001]
  • (PMID = 18349828.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A5047; United Kingdom / British Heart Foundation / / BS/06/005/20340; United Kingdom / British Heart Foundation / / BB2000003; United Kingdom / British Heart Foundation / / BS06/005
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2359649; NLM/ UKMS3369
  •  go-up   go-down


3. Røkke O, Faerden AE, Øvrebø K: [Transanal endoscopic microsurgery for tumours in rectum]. Tidsskr Nor Laegeforen; 2007 Nov 15;127(22):2954-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Transanal endoskopisk mikrokirurgi ved svulster i rectum.
  • BACKGROUND: Rectal tumors up to 25 cm from the anal verge may be resected by transanal endoscopic microsurgery (TEM).
  • TEM is suitable for resection of benign adenomas, but can also be used for selected malignant tumours.
  • Selected malignant tumours (like small carcinoid tumours and early stage [Tis, T1] adencarcinomas) with higer moderate differentiation may be resected by TEM with the same oncological result as open surgery.
  • TEM is especially suitable to resect benign adenomas, and may also have a place as primary treatment of selected malignant tumours in Norway.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local. Postoperative Complications / diagnosis. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026244.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 50
  •  go-up   go-down


Advertisement
4. Prete F, Prete FP, Nitti P, De Luca R, Vincenti L: [Evolution of surgery for cancer of the anorectal junction]. Chir Ital; 2007 Nov-Dec;59(6):763-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Evoluzione chirurgica per i tumori del giunto ano-rettale.
  • Certain aspects of the epidemiology, classification and therapy of adenocarcinoma of the anorectal junction (< 5 cm from the anal verge) are not well standardised to date.
  • Assessment of anal sphincter function recovery one year after restoration of bowel continuity showed good continence in 76% of the patients; 2 patients have a permanent ostomy.
  • [MeSH-major] Adenocarcinoma / surgery. Anal Canal / surgery. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colostomy. Female. Follow-Up Studies. Humans. Ileostomy. Laparoscopy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Postoperative Care. Preoperative Care. Proctoscopy. Radiotherapy, Adjuvant. Rectum / pathology. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360980.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Walsh N, Larkin A, Kennedy S, Connolly L, Ballot J, Ooi W, Gullo G, Crown J, Clynes M, O'Driscoll L: Expression of multidrug resistance markers ABCB1 (MDR-1/P-gp) and ABCC1 (MRP-1) in renal cell carcinoma. BMC Urol; 2009;9:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mechanisms of MDR in renal cancer are not fully understood and the specific contribution of ABC transporter proteins which have been implicated in the chemoresistance of various cancers has not been fully defined in this disease.
  • CONCLUSION: Although these findings do not prove a causal role, the high frequency of tumours expressing these efflux pumps suggests that they may be important contributors to the chemoresistance of this tumour type.
  • [MeSH-major] Carcinoma, Renal Cell / metabolism. Kidney Neoplasms / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / administration & dosage. Biomarkers, Tumor / metabolism. Female. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. P-Glycoproteins. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1997 Jun;50(6):465-71 [9378810.001]
  • [Cites] Br J Urol. 1997 Jul;80(1):11-7 [9240173.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1611-5 [9815963.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):155-63 [15645438.001]
  • [Cites] J Neurooncol. 2005 Sep;74(2):113-21 [16193381.001]
  • [Cites] BMC Cancer. 2006;6:293 [17177989.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1267-72 [17593618.001]
  • [Cites] Anticancer Res. 2007 May-Jun;27(3A):1325-30 [17593626.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4B):2115-20 [17695494.001]
  • [Cites] Am J Epidemiol. 2007 Oct 15;166(8):932-40 [17656615.001]
  • [Cites] BJU Int. 2008 Nov;102(10):1376-80 [18727618.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):341-3 [19160702.001]
  • [Cites] BMC Cancer. 2009;9:82 [19284623.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Jun;64(1):11-25 [19343348.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3584-90 [19487381.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2859-67 [10561363.001]
  • [Cites] N Engl J Med. 2000 Nov 2;343(18):1305-11 [11058675.001]
  • [Cites] Jpn J Cancer Res. 2001 Nov;92(11):1220-4 [11714447.001]
  • [Cites] Hybrid Hybridomics. 2001;20(5-6):333-41 [11839251.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):121-8 [12017273.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3127-32 [12915604.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):579-91 [15286738.001]
  • [Cites] Int J Cancer. 2004 Nov 1;112(2):286-94 [15352042.001]
  • [Cites] Int J Urol. 2004 Sep;11(9):721-7 [15379935.001]
  • [Cites] J Natl Cancer Inst. 1989 Jun 7;81(11):844-9 [2724349.001]
  • [Cites] Eur Urol. 1990;17(1):72-5 [1969346.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2993-8 [1350506.001]
  • [Cites] Eur Urol. 1993;24(1):156-60 [8103456.001]
  • [Cites] Oncology. 1994 Jul-Aug;51(4):309-13 [7911563.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(5):491-5 [8599874.001]
  • [Cites] J Urol. 1996 Aug;156(2 Pt 1):506-11 [8683726.001]
  • [Cites] Kidney Int Suppl. 1998 Apr;65:S11-7 [9551426.001]
  • (PMID = 19552816.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / multidrug resistance-associated protein 1
  • [Other-IDs] NLM/ PMC2723136
  •  go-up   go-down


6. Chen B, Wang Y, Kane SE, Chen S: Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells. J Mol Endocrinol; 2008 Nov;41(5):367-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of sensitivity to tamoxifen in estrogen receptor-positive and Herceptin-resistant breast cancer cells.
  • ERBB2 overexpression in estrogen receptor (ER)-positive breast cancer cells such as BT474 (BT) cells has been found to confer resistance to tamoxifen, and suppression of ERBB2 improves the antiproliferative effects of tamoxifen.
  • In this study, the responsiveness to tamoxifen in the BT/HerR, Herceptin-resistant BT cell lines established through constant Herceptin exposure, was evaluated.
  • Compared with BT cells, improvement of sensitivity to tamoxifen in BT/HerR was demonstrated by ER functional analysis and cell proliferation assay.
  • Tamoxifen in the resistant cell line was found to inhibit 17beta-estradiol-stimulating estrogen-responsive gene pS2 expression more effectively than in BT cells in real-time PCR assay.
  • Western blot analysis showed that cross-phosphorylation between ER and downstream components of ERBB2 was attenuated in BT/HerR cells.
  • ER redistribution from cytoplasm to nucleus could be found in these cells through immunofluorescence and confocal studies, and importantly, chromatin immunoprecipitation studies demonstrated that tamoxifen induced occupancy of the pS2 promoter by ER and nuclear receptor corepressor (NCOR1) instead of coactivator NCOA3 in these cells.
  • Finally, combination of tamoxifen and Herceptin was found to improve the sensitivity of BT/HerR cells to Herceptin.
  • Our results suggest that the ER genomic pathway in the ER-positive and Herceptin-resistant breast cancer cells may be reactivated, allowing tamoxifen therapy to be effective again, and a combination of tamoxifen and Herceptin can be a potential therapeutic strategy for ER-positive and Herceptin-resistant human breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2005;93 Suppl 1:S11-8 [16247595.001]
  • [Cites] Breast Cancer Res Treat. 2005 Aug;92(3):251-63 [16155796.001]
  • [Cites] Mol Pharmacol. 2006 Nov;70(5):1534-41 [16887935.001]
  • [Cites] BMC Cancer. 2007;7:59 [17407600.001]
  • [Cites] Gene. 2007 Jul 15;396(2):358-68 [17507182.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9018-23 [17909003.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9609-14 [10931950.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3471-9 [11032587.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5887-94 [11059787.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9817-24 [11139588.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5985-91 [11507039.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7184-8 [11585753.001]
  • [Cites] Oncology. 2001;61 Suppl 2:43-9 [11694787.001]
  • [Cites] J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7 [11752009.001]
  • [Cites] Mol Endocrinol. 2002 Jan;16(1):116-27 [11773443.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):783-91 [12115478.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4132-41 [12124352.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8 [12415108.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):707-17 [12479367.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):331S-6S [14734488.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1409-20 [14977844.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3621-8 [15173068.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):926-35 [15199112.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 [1350088.001]
  • [Cites] Oncogene. 1995 Jun 15;10(12):2435-46 [7784095.001]
  • [Cites] Science. 1995 Dec 1;270(5241):1491-4 [7491495.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3350-8 [8764133.001]
  • [Cites] Mol Endocrinol. 1997 Jun;11(6):657-66 [9171229.001]
  • [Cites] Science. 1997 Aug 15;277(5328):965-8 [9252329.001]
  • [Cites] Breast Cancer Res Treat. 2005 May;91(2):187-201 [15868447.001]
  • [Cites] Nat Clin Pract Oncol. 2006 May;3(5):269-80 [16683005.001]
  • (PMID = 18768663.001).
  • [ISSN] 1479-6813
  • [Journal-full-title] Journal of molecular endocrinology
  • [ISO-abbreviation] J. Mol. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01 ES008258; United States / NCI NIH HHS / CA / CA44735; United States / NIEHS NIH HHS / ES / ES08258; United States / NCI NIH HHS / CA / R01 CA044735; United States / NCI NIH HHS / CA / R01 CA044735-19; United States / NCI NIH HHS / CA / CA33572; United States / NCI NIH HHS / CA / CA033572-27; United States / NCI NIH HHS / CA / P30 CA033572-27; United States / NCI NIH HHS / CA / P30 CA033572; United States / NIEHS NIH HHS / ES / R01 ES008258-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protein Isoforms; 0 / Receptors, Estrogen; 0 / Transcription Factors; 094ZI81Y45 / Tamoxifen; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / NCOA1 protein, human; EC 2.3.1.48 / Nuclear Receptor Coactivator 1; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  • [Other-IDs] NLM/ NIHMS368261; NLM/ PMC3503452
  •  go-up   go-down


7. Balagurunathan Y, Morse DL, Hostetter G, Shanmugam V, Stafford P, Shack S, Pearson J, Trissal M, Demeure MJ, Von Hoff DD, Hruby VJ, Gillies RJ, Han H: Gene expression profiling-based identification of cell-surface targets for developing multimeric ligands in pancreatic cancer. Mol Cancer Ther; 2008 Sep;7(9):3071-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to cooperative binding, multimeric ligands can have high avidity for cells (tumor) expressing all targeting proteins and only show minimal binding to cells (normal tissues) expressing none or only some of the targets.
  • Identifying combinations of targets that concurrently express in tumor cells but not in normal cells is a challenging task.
  • The expression data for genes that encode proteins with cell-surface epitopes were then extracted from the database and analyzed using a novel multivariate rule-based computational approach to identify gene combinations that are expressed at an efficient binding level in tumors but not in normal tissues.
  • These combinations were further ranked according to the proportion of tumor samples that expressed the sets at efficient levels.
  • Protein expression of the genes contained in the top ranked combinations was confirmed using immunohistochemistry on a pancreatic tumor tissue and normal tissue microarrays.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 2001 Oct 1;45(2):83-6 [11590619.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(9):1685-8 [18205159.001]
  • [Cites] J Comput Biol. 2002;9(1):105-26 [11911797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Jan 5;14(1):211-5 [14684330.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] J Am Chem Soc. 2004 May 12;126(18):5730-9 [15125666.001]
  • [Cites] J Cell Biol. 1991 Feb;112(3):385-95 [1991789.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Expert Opin Ther Targets. 2004 Dec;8(6):565-86 [15584863.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):1882-92 [15531581.001]
  • [Cites] J Nucl Med. 2005 Jan;46 Suppl 1:141S-50S [15653662.001]
  • [Cites] Genome Res. 2005 Mar;15(3):443-50 [15741514.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):400-9 [15822916.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Mar;5(2):171-81 [15833047.001]
  • [Cites] Anal Biochem. 2005 Jul 1;342(1):69-77 [15958182.001]
  • [Cites] Expert Rev Proteomics. 2004 Aug;1(2):185-92 [15966813.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e70 [15783258.001]
  • [Cites] Ann Biomed Eng. 2005 Aug;33(8):1113-24 [16133919.001]
  • [Cites] Drug Resist Updat. 2005 Dec;8(6):381-402 [16309948.001]
  • [Cites] J Nucl Med. 2006 May;47(5):763-9 [16644745.001]
  • [Cites] Org Biomol Chem. 2006 May 21;4(10):1958-65 [16688341.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2006 Dec;50(4):248-64 [17043623.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3734-44 [17530026.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1256-60 [11888886.001]
  • (PMID = 18765825.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA095944-02; United States / NCI NIH HHS / CA / P01 CA109552-039001; United States / NCI NIH HHS / CA / P01 CA109552-049001; United States / NCI NIH HHS / CA / R01 CA097360-04; United States / NCI NIH HHS / CA / P01 CA109552-01A10003; United States / NCI NIH HHS / CA / R33 CA095944-03; United States / NCI NIH HHS / CA / R21 CA095944; United States / NCI NIH HHS / CA / CA109552-03; United States / NCI NIH HHS / CA / CA097360; United States / NCI NIH HHS / CA / CA095944-01; United States / NCI NIH HHS / CA / CA109552-040003; United States / NCI NIH HHS / CA / P01 CA109552-01A17991; United States / NCI NIH HHS / CA / CA109552-01A17991; United States / NCI NIH HHS / CA / CA095944-03; United States / NCI NIH HHS / CA / P01 CA109552-029001; United States / NCI NIH HHS / CA / P01 CA109552-040003; United States / NCI NIH HHS / CA / R01 CA097360; United States / NCI NIH HHS / CA / R33 CA095944-02; United States / NCI NIH HHS / CA / CA097360-01A1; United States / NCI NIH HHS / CA / CA109552-01A19001; United States / NCI NIH HHS / CA / R01 CA097360-03; United States / NCI NIH HHS / CA / CA095944-04; United States / NCI NIH HHS / CA / CA109552-01A10003; United States / NCI NIH HHS / CA / CA109552-01A1; United States / NCI NIH HHS / CA / CA097360-04; United States / NCI NIH HHS / CA / R01 CA097360-01A1; United States / NCI NIH HHS / CA / CA109552-029001; United States / NCI NIH HHS / CA / R21 CA095944-01; United States / NCI NIH HHS / CA / R33 CA095944-04; United States / NCI NIH HHS / CA / P01 CA109552-04; United States / NCI NIH HHS / CA / CA109552-030003; United States / NCI NIH HHS / CA / CA109552-049001; United States / NCI NIH HHS / CA / CA097360-03; United States / NCI NIH HHS / CA / CA109552-039001; United States / NCI NIH HHS / CA / P01 CA109552-01A1; United States / NCI NIH HHS / CA / P01 CA109552-03; United States / NCI NIH HHS / CA / R01 CA097360-02; United States / NCI NIH HHS / CA / CA097360-02; United States / NCI NIH HHS / CA / P01 CA109552-01A19001; United States / NCI NIH HHS / CA / CA109552-020003; United States / NCI NIH HHS / CA / P01 CA109552; United States / NCI NIH HHS / CA / CA109552; United States / NCI NIH HHS / CA / CA095944; United States / NCI NIH HHS / CA / CA109552-02; United States / NCI NIH HHS / CA / CA109552-04; United States / NCI NIH HHS / CA / P01 CA109552-030003; United States / NCI NIH HHS / CA / R01 CA097360-05A1; United States / NCI NIH HHS / CA / P01 CA109552-020003; United States / NCI NIH HHS / CA / R33 CA095944; United States / NCI NIH HHS / CA / P01 CA109552-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ligands
  • [Other-IDs] NLM/ NIHMS69565; NLM/ PMC2567866
  •  go-up   go-down


8. Ozvegy-Laczka C, Laczkó R, Hegedus C, Litman T, Várady G, Goda K, Hegedus T, Dokholyan NV, Sorrentino BP, Váradi A, Sarkadi B: Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter. J Biol Chem; 2008 Sep 19;283(38):26059-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] ATP-Binding Cassette Transporters / chemistry. ATP-Binding Cassette Transporters / metabolism. Antibodies, Monoclonal / chemistry. Neoplasm Proteins / chemistry. Neoplasm Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PARAFORMALDEHYDE .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • Hazardous Substances Data Bank. CYSTEINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharm Res. 2005 Mar;22(3):458-64 [15835752.001]
  • [Cites] Structure. 2008 Jul;16(7):1010-8 [18611374.001]
  • [Cites] Biometals. 2005 Aug;18(4):349-58 [16158227.001]
  • [Cites] J Exp Ther Oncol. 2006;5(3):205-22 [16528971.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3458-64 [11309308.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7 [11437380.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1028-34 [11533706.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):626-30 [11807788.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4594-601 [12393637.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):47980-90 [12374800.001]
  • [Cites] Mol Cancer Ther. 2002 Apr;1(6):417-25 [12477054.001]
  • [Cites] Biochem J. 2003 Aug 1;373(Pt 3):767-74 [12741957.001]
  • [Cites] Br J Cancer. 2003 Nov 17;89(10):1971-8 [14612912.001]
  • [Cites] Mol Pharmacol. 2004 Jun;65(6):1485-95 [15155841.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24218-25 [15044468.001]
  • [Cites] Pharm Res. 2004 May;21(5):719-35 [15180326.001]
  • [Cites] Anal Biochem. 1986 Oct;158(1):233-7 [2432803.001]
  • [Cites] J Immunol. 1996 Oct 1;157(7):2939-46 [8816400.001]
  • [Cites] Fold Des. 1998;3(6):577-87 [9889167.001]
  • [Cites] J Biol Chem. 2005 Feb 11;280(6):4219-27 [15557326.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1770-7 [15753373.001]
  • [Cites] J Biol Chem. 2005 Nov 4;280(44):36926-34 [16107343.001]
  • [Cites] Cancer Sci. 2005 Dec;96(12):866-72 [16367905.001]
  • [Cites] PLoS Comput Biol. 2006 Jul 7;2(7):e85 [16839198.001]
  • [Cites] Physiol Rev. 2006 Oct;86(4):1179-236 [17015488.001]
  • [Cites] Cancer Metastasis Rev. 2007 Mar;26(1):39-57 [17323127.001]
  • [Cites] J Biol Chem. 2007 Sep 21;282(38):27841-6 [17686774.001]
  • [Cites] J Struct Biol. 2008 Apr;162(1):63-74 [18249138.001]
  • [Cites] J Mol Biol. 2008 May 16;378(5):1052-63 [18423665.001]
  • [Cites] Trends Biotechnol. 2005 Sep;23(9):450-5 [16038997.001]
  • (PMID = 18644784.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCG2 protein, human; 0 / ATP Binding Cassette Transporter, Sub-Family G, Member 2; 0 / ATP-Binding Cassette Transporters; 0 / Antibodies, Monoclonal; 0 / Cross-Linking Reagents; 0 / Epitopes; 0 / Membrane Transport Proteins; 0 / Neoplasm Proteins; 0 / Polymers; 1HG84L3525 / Formaldehyde; K848JZ4886 / Cysteine; T8ID5YZU6Y / Dithiothreitol; Y19UC83H8E / paraform
  • [Other-IDs] NLM/ PMC3258862
  •  go-up   go-down


9. Bader FG, Bouchard R, Keller R, Mirow L, Czymek R, Habermann JK, Fritsch H, Bruch HP, Roblick UJ: [Progress in diagnostics of anorectal disorders. Part I: anatomic background and clinical and neurologic procedures]. Chirurg; 2008 May;79(5):401-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three-dimensional endosonography and technical advances in flexible endoscopy using high-resolution chromoendoscopy and narrow-band imaging enable exact staging and diagnosis, even of malignancies in earliest stages.
  • Furthermore new in-vivo staining methods combined with high-resolution imaging facilitate the discrimination of inflammatory and neoplastic lesions, which often lead to diagnostic difficulties in chronic inflammatory bowel disease.
  • [MeSH-major] Anus Diseases / pathology. Anus Neoplasms / pathology. Rectal Diseases / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Anal Canal / pathology. Anal Canal / physiopathology. Electromyography. Endosonography. Evoked Potentials, Motor / physiology. Fecal Incontinence / diagnosis. Fecal Incontinence / physiopathology. Intestinal Polyps / diagnosis. Intestinal Polyps / pathology. Intestinal Polyps / physiopathology. Neoplasm Staging. Proctoscopy. Rectum / pathology. Rectum / physiopathology. Spinal Nerve Roots / physiopathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Disorders.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterol Clin North Am. 2003 Jun;32(2):463-76, v [12858602.001]
  • [Cites] Inflamm Bowel Dis. 2007 May;13(5):640-1 [17221857.001]
  • [Cites] Endoscopy. 2004 Dec;36(12):1094-8 [15578301.001]
  • [Cites] Muscle Nerve. 2005 Jul;32(1):110-2 [15880519.001]
  • [Cites] Neurophysiol Clin. 2004 Oct;34(3-4):153-7 [15501685.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):732-60 [10029631.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv7-11 [12746262.001]
  • [Cites] Endoscopy. 2003 Jun;35(6):511-4 [12783350.001]
  • [Cites] Neurourol Urodyn. 2001;20(6):669-82 [11746548.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):131-40 [15043282.001]
  • [Cites] Gastroenterology. 2007 Oct;133(4):1069-74 [17919481.001]
  • [Cites] Gut. 2008 Jan;57(1):59-64 [17681999.001]
  • [Cites] Semin Surg Oncol. 1998 Sep;15(2):66-71 [9730411.001]
  • [Cites] Neurogastroenterol Motil. 2006 Jul;18(7):507-19 [16771766.001]
  • [Cites] Endoscopy. 2007 Nov;39(11):937-41 [18008201.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Endoscopy. 2007 Jun;39(6):497-501 [17554643.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):666-71 [11357026.001]
  • [Cites] Z Gastroenterol. 2007 May;45(5):397-417 [17503320.001]
  • [Cites] Endoscopy. 2005 Apr;37(4):357-61 [15824947.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):808-16 [15784023.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2167-73 [16181364.001]
  • [Cites] Muscle Nerve. 2006 Mar;33(3):324-33 [16025529.001]
  • [Cites] Gynecol Obstet Invest. 2001;51(3):187-90 [11306907.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Sep;3(9):897-902 [16234028.001]
  • [Cites] J Clin Gastroenterol. 2006 Feb;40(2):96-103 [16394868.001]
  • [Cites] Dis Colon Rectum. 2000 May;43(5):633-6; discussion 636-7 [10826423.001]
  • [Cites] Digestion. 2004;69(2):112-22 [15087578.001]
  • [Cites] Gastrointest Endosc. 2002 May;55(6):687-94 [11979251.001]
  • [Cites] Neurogastroenterol Motil. 2004 Apr;16(2):241-50 [15086878.001]
  • [Cites] Dis Colon Rectum. 2002 Feb;45(2):188-94 [11852331.001]
  • [Cites] Int J Colorectal Dis. 2007 Nov;22(11):1339-46 [17619888.001]
  • [Cites] Am J Surg. 2006 Jul;192(1):89-97 [16769283.001]
  • [Cites] Gastroenterology. 2001 Feb;120(3):763-81 [11179249.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Chir Ital. 2004 Jan-Feb;56(1):31-6 [15038645.001]
  • (PMID = 18414817.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


10. Duong HS, Le AD, Zhang Q, Messadi DV: A novel 3-dimensional culture system as an in vitro model for studying oral cancer cell invasion. Int J Exp Pathol; 2005 Dec;86(6):365-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tissue microenvironment plays a critical role in tumour growth and invasion.
  • [MeSH-major] Mouth Neoplasms / pathology
  • [MeSH-minor] Blotting, Western / methods. Cell Hypoxia. Coculture Techniques / methods. Electrophoresis, Polyacrylamide Gel / methods. Fibroblasts / pathology. Humans. Mouth Mucosa / pathology. Neoplasm Invasiveness. Plasminogen Activator Inhibitor 1 / pharmacology. Urokinase-Type Plasminogen Activator / pharmacology

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):384-91 [10469338.001]
  • [Cites] Mol Med Today. 2000 Apr;6(4):157-62 [10740254.001]
  • [Cites] Anal Biochem. 2000 Jun 1;281(2):236-8 [10870843.001]
  • [Cites] Oral Oncol. 2000 Jul;36(4):365-72 [10899676.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):25-40 [10949579.001]
  • [Cites] Pathobiology. 2000 May-Jun;68(3):99-105 [11174066.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):266-76 [11181773.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):799-807 [11221858.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3844-6 [11325861.001]
  • [Cites] Exp Cell Res. 2001 Jul 1;267(1):88-94 [11412041.001]
  • [Cites] Melanoma Res. 2001 Aug;11(4):417-21 [11479431.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):38-47 [11902584.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1847-53 [11912164.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Clin Exp Metastasis. 2002;19(3):193-207 [12067200.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Mar;35(3):339-48 [12531247.001]
  • [Cites] Am J Pathol. 2003 May;162(5):1579-89 [12707042.001]
  • [Cites] Clin Exp Metastasis. 2003;20(3):237-50 [12741682.001]
  • [Cites] Br J Cancer. 2003 Sep 15;89(6):1042-7 [12966423.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):348-57 [14648700.001]
  • [Cites] Thromb Haemost. 2004 Mar;91(3):438-49 [14983218.001]
  • [Cites] Exp Mol Med. 2004 Feb 29;36(1):57-64 [15031672.001]
  • [Cites] Exp Cell Res. 2004 Apr 15;295(1):48-58 [15051489.001]
  • [Cites] Exp Cell Res. 2004 Jun 10;296(2):151-62 [15149846.001]
  • [Cites] J Surg Res. 2004 Aug;120(2):295-303 [15234226.001]
  • [Cites] Antioxid Redox Signal. 2004 Aug;6(4):777-91 [15242559.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):943-7 [15313864.001]
  • [Cites] Mol Cell Biochem. 2004 Jun;261(1-2):117-22 [15362494.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jan;87(1):75-9 [2296606.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(18):6939-43 [2169614.001]
  • [Cites] Physiol Rev. 1993 Jan;73(1):161-95 [8419965.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):286-92 [9766559.001]
  • [Cites] Int J Cancer. 1999 Feb 9;80(4):617-23 [9935166.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):883-7 [10706099.001]
  • (PMID = 16309542.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Plasminogen Activator Inhibitor 1; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ PMC2517444
  •  go-up   go-down


11. Ruggiero A, Holland JP, Lewis JS, Grimm J: Cerenkov luminescence imaging of medical isotopes. J Nucl Med; 2010 Jul;51(7):1123-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies.
  • The change in light emission intensity versus time was concordant with radionuclide decay and was also found to correlate linearly with both the activity concentration and the measured PET signal (percentage injected dose per gram).
  • In vivo studies conducted in male severe combined immune deficient mice bearing PSMA-positive, subcutaneous LNCaP tumors demonstrated that tumor-specific uptake of (89)Zr-DFO-J591 could be visualized by both immuno-PET and CLI.
  • [MeSH-minor] Alpha Particles. Animals. Antibodies, Monoclonal. Beta Particles. Deferoxamine. Drug Evaluation, Preclinical. Electrons. Female. Humans. Male. Mice. Neoplasm Transplantation / diagnostic imaging. Neoplasms / diagnostic imaging. Neoplasms / metabolism. Phantoms, Imaging. Positron-Emission Tomography. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / diagnostic imaging. Prostatic Neoplasms / immunology. Radioisotopes. Tissue Distribution. Zirconium

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DESFERRIOXAMINE .
  • Hazardous Substances Data Bank. ZIRCONIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5237-43 [11016653.001]
  • [Cites] Nucl Med Biol. 2009 Oct;36(7):729-39 [19720285.001]
  • [Cites] Science. 2001 Nov 16;294(5546):1537-40 [11711678.001]
  • [Cites] Cell Death Differ. 2002 Jun;9(6):593-4 [12032666.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):610-7 [12679407.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1271-81 [12902418.001]
  • [Cites] J Nucl Med. 2003 Oct;44(10):1663-70 [14530484.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4489-97 [15240541.001]
  • [Cites] Anal Biochem. 1971 Aug;42(2):360-2 [5118580.001]
  • [Cites] Anal Biochem. 1980 Nov 15;109(1):12-7 [6258454.001]
  • [Cites] Anal Biochem. 1984 Feb;136(2):515-9 [6721149.001]
  • [Cites] Nucl Med Biol. 1997 Jan;24(1):35-43 [9080473.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3629-34 [9288760.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4055-60 [9751609.001]
  • [Cites] Phys Med Biol. 1999 Mar;44(3):781-99 [10211810.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14404-9 [16183744.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1337-45 [16832633.001]
  • [Cites] PLoS One. 2007;2(3):e267 [17342201.001]
  • [Cites] Nat Med. 2007 Aug;13(8):992-7 [17676052.001]
  • [Cites] J Nucl Med. 2007 Sep;48(9):1527-35 [17704248.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):580-9 [18385732.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Sep15;60(12):1371-82 [18514364.001]
  • [Cites] J Nucl Med. 2009 Jan;50(1):123-31 [19091906.001]
  • [Cites] J Nucl Med. 2009 Jun;50(6):974-81 [19443585.001]
  • [Cites] Phys Med Biol. 2009 Aug 21;54(16):N355-65 [19636082.001]
  • [Cites] J Nucl Med. 2009 Nov;50(11):1828-36 [19837762.001]
  • [Cites] Phys Med Biol. 2009 Nov 21;54(22):6757-71 [19847018.001]
  • [Cites] Phys Med Biol. 2010 Jan 21;55(2):483-95 [20023328.001]
  • [Cites] PLoS One. 2010;5(1):e8859 [20111600.001]
  • [Cites] Mol Imaging. 2010 Feb;9(1):1-20 [20128994.001]
  • [Cites] J Nucl Med. 2010 Mar;51(3):333-6 [20150252.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6095-100 [11085533.001]
  • (PMID = 20554722.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA096945; United States / NCI NIH HHS / CA / R24 CA083084-07; United States / NCI NIH HHS / CA / P30 CA08748; United States / NCI NIH HHS / CA / R25 CA096945-07; United States / NCI NIH HHS / CA / P30 CA008748; United States / NCI NIH HHS / CA / P30 CA008748-44S5; United States / NCI NIH HHS / CA / R25T CA046945; United States / NCI NIH HHS / CA / R24 CA83084; United States / NCI NIH HHS / CA / R24 CA083084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 0 / Radiopharmaceuticals; C6V6S92N3C / Zirconium; EC 3.4.21.77 / Prostate-Specific Antigen; J06Y7MXW4D / Deferoxamine
  • [Other-IDs] NLM/ NIHMS274804; NLM/ PMC3068779
  •  go-up   go-down


12. Srisomsap C, Sawangareetrakul P, Subhasitanont P, Chokchaichamnankit D, Chiablaem K, Bhudhisawasdi V, Wongkham S, Svasti J: Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol; 2010;2010:437143
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Bile Duct Neoplasms / secretion. Bile Ducts, Intrahepatic / secretion. Carcinoma, Hepatocellular / secretion. Cholangiocarcinoma / secretion. Liver Neoplasms / secretion. Neoplasm Proteins / secretion. Proteomics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Line, Tumor. Cell Survival. Culture Media, Conditioned. Electrophoresis, Gel, Two-Dimensional. Electrophoresis, Polyacrylamide Gel. Female. Humans. Male. Middle Aged. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 2000 Feb;11(1):13-8 [10679337.001]
  • [Cites] Int J Biochem Cell Biol. 2009 May;41(5):1148-56 [18996218.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5951-5 [12185597.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3684-91 [14506159.001]
  • [Cites] Proteomics. 2004 Apr;4(4):1135-44 [15048994.001]
  • [Cites] Mol Cell Proteomics. 2004 Jul;3(7):715-28 [15084671.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):938-45 [15105812.001]
  • [Cites] Pathol Int. 2004 Sep;54(9):688-92 [15363037.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Southeast Asian J Trop Med Public Health. 1978 Jun;9(2):215-9 [214874.001]
  • [Cites] Am J Pathol. 1985 Feb;118(2):203-8 [2578738.001]
  • [Cites] Am J Pathol. 1989 Jun;134(6):1347-63 [2474256.001]
  • [Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]
  • [Cites] Int J Cancer. 1994 Jun 1;57(5):691-5 [8194877.001]
  • [Cites] Clin Exp Dermatol. 2005 May;30(3):261-6 [15807686.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jun;6(6):449-61 [15928709.001]
  • [Cites] Electrophoresis. 2005 Jul;26(14):2779-85 [15966010.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3173-82 [16035111.001]
  • [Cites] Curr Gastroenterol Rep. 2006 Feb;8(1):30-7 [16510032.001]
  • [Cites] J Proteome Res. 2006 Apr;5(4):899-906 [16602697.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1083-92 [17284061.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Sep;133(9):910-8 [17875858.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] Cancer Res. 2008 Feb 1;68(3):715-23 [18245471.001]
  • [Cites] Adv Exp Med Biol. 2008;617:453-61 [18497069.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Jun;233(6):708-20 [18408141.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6100-8 [18676832.001]
  • [Cites] J Proteome Res. 2008 Oct;7(10):4247-55 [18707159.001]
  • [Cites] Dig Dis Sci. 2008 Dec;53(12):3213-7 [18465243.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):380-9 [19012429.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):331-71 [11917092.001]
  • (PMID = 20069059.001).
  • [ISSN] 1110-7251
  • [Journal-full-title] Journal of biomedicine & biotechnology
  • [ISO-abbreviation] J. Biomed. Biotechnol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Culture Media, Conditioned; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2801507
  •  go-up   go-down


13. Wu M, Jung L, Cooper AB, Fleet C, Chen L, Breault L, Clark K, Cai Z, Vincent S, Bottega S, Shen Q, Richardson A, Bosenburg M, Naber SP, DePinho RA, Kuperwasser C, Robinson MO: Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice. Proc Natl Acad Sci U S A; 2009 Apr 28;106(17):7022-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor development in the HIM model proceeds through defined histological stages of hyperplasia, DCIS to invasive carcinoma.
  • Moreover, HIM tumors display characteristic responses to targeted therapies, such as HER2 inhibitors, further validating the utility of these models in preclinical compound testing.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cyclin D1 / metabolism. Disease Models, Animal. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Mice. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. RNA Interference. Receptor, ErbB-2 / antagonists & inhibitors. Receptor, ErbB-2 / genetics. Receptor, ErbB-2 / metabolism. Simian virus 40 / genetics. Simian virus 40 / metabolism. Telomerase / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism. Xenograft Model Antitumor Assays. ras Proteins / genetics. ras Proteins / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):415-8 [11920593.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 1:S15-9 [11521715.001]
  • [Cites] Endocrinology. 2002 Dec;143(12):4886-96 [12446616.001]
  • [Cites] Cancer Cell. 2003 May;3(5):483-95 [12781366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Cancer Chemother Biol Response Modif. 2003;21:223-33 [15338747.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5291-8 [1394133.001]
  • [Cites] Anal Quant Cytol Histol. 1992 Dec;14(6):433-45 [1363346.001]
  • [Cites] J Biol Chem. 1996 Mar 29;271(13):7673-8 [8631805.001]
  • [Cites] Pathol Int. 1998 Jul;48(7):518-25 [9701014.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):609-12 [9792821.001]
  • [Cites] Genes Dev. 1999 Sep 15;13(18):2388-99 [10500096.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2460-8 [15710948.001]
  • [Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]
  • [Cites] Hum Pathol. 2008 Feb;39(2):167-74 [18045647.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Oct 15;114(2):154-5 [10549274.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):50-65 [11156605.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Am J Nurs. 2001 Apr;101(4):11 [11301675.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • (PMID = 19369208.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.7.49 / Telomerase; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


14. Groseclose MR, Massion PP, Chaurand P, Caprioli RM: High-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue microarrays using MALDI imaging mass spectrometry. Proteomics; 2008 Sep;8(18):3715-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A TMA section containing 112 needle core biopsies from lung-tumor patients was analyzed using MS and the data were correlated to a serial hematoxylin and eosin (H&E)-stained section having various histological regions marked, including cancer, non-cancer, and normal ones.
  • The ability to detect and characterize tumor marker proteins for a large cohort of FFPE samples in a high-throughput approach will be of significant benefit not only to investigators studying tumor biology, but also to clinicians for diagnostic and prognostic purposes.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 1985 Aug;33(8):845-53 [3894502.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Lab Invest. 1990 Nov;63(5):722-4 [2232717.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Toxicol Pathol. 2005;33(1):92-101 [15805060.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Lab Invest. 2005 Nov;85(11):1405-15 [16155593.001]
  • [Cites] Mol Cell Proteomics. 2005 Nov;4(11):1741-53 [16091476.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10642-5 [16322204.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Dec 15;172(12):1556-62 [16179643.001]
  • [Cites] J Proteome Res. 2005 Nov-Dec;4(6):2404-11 [16335994.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):809-19 [16448055.001]
  • [Cites] Anal Chem. 2006 Feb 1;78(3):827-34 [16448057.001]
  • [Cites] J Histochem Cytochem. 2006 Jun;54(6):739-43 [16399996.001]
  • [Cites] J Mass Spectrom. 2006 Jun;41(6):705-16 [16718638.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1975-83 [16849436.001]
  • [Cites] Anal Chem. 2006 Oct 15;78(20):7145-53 [17037914.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2889-900 [17081040.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):65-76 [16799640.001]
  • [Cites] J Proteome Res. 2007 Mar;6(3):1038-47 [17266348.001]
  • [Cites] J Mass Spectrom. 2007 Feb;42(2):254-62 [17230433.001]
  • [Cites] J Proteome Res. 2007 Apr;6(4):1295-305 [17291023.001]
  • [Cites] Nat Methods. 2007 Oct;4(10):828-33 [17901873.001]
  • [Cites] J Proteome Res. 2007 Nov;6(11):4127-34 [17939699.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Gen Intern Med. 2008 Jan;23 Suppl 1:78-84 [18095050.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):49-52 [12086887.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Proteomics. 2003 Apr;3(4):413-21 [12687609.001]
  • [Cites] J Mass Spectrom. 2003 Jul;38(7):699-708 [12898649.001]
  • [Cites] Lancet. 2003 Aug 9;362(9382):433-9 [12927430.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):190-9 [14983931.001]
  • [Cites] Lab Invest. 1986 Aug;55(2):244-8 [3525985.001]
  • (PMID = 18712763.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM058008; United States / NCI NIH HHS / CA / R01 CA102353; United States / NIGMS NIH HHS / GM / 5R01GM58008-08D; United States / NIGMS NIH HHS / GM / R01 GM058008-10; United States / NIGMS NIH HHS / GM / GM058008-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fixatives; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde
  • [Other-IDs] NLM/ NIHMS227070; NLM/ PMC2927989
  •  go-up   go-down


15. Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM: Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One; 2008;3(6):e2425
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Elucidation of the repertoire of secreted and cell surface proteins of tumor cells is relevant to molecular diagnostics, tumor imaging and targeted therapies.
  • We have characterized the cell surface proteome and the proteins released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells enriched from ascites fluid.
  • Proteomic analysis indicated extensive shedding from extra-cellular domains of proteins expressed on the cell surface, and remarkably high secretion rates for some proteins (nanograms per million cells per hour).
  • Cell surface and secreted proteins identified by in-depth proteomic profiling of ovarian cancer cells may provide new targets for diagnosis and therapy.
  • [MeSH-major] Neoplasm Proteins / secretion. Ovarian Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Extracellular Space / metabolism. Female. Humans. Tandem Mass Spectrometry


16. Gerstner AO, Laffers W: [Cytomics and predictive medicine for oncology]. HNO; 2008 Apr;56(4):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To use this huge amount of data for treatment decisions in an individual patient, novel bioinformatic concepts are needed in order to predict the individual course of a disease.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Physiological Phenomena. Medical Oncology / methods. Neoplasm Proteins / metabolism. Neoplasms / diagnosis. Neoplasms / metabolism. Proteome / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):211-8 [17291754.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):179-96 [15113093.001]
  • [Cites] Cytometry A. 2007 Dec;71(12):991-1002 [17929292.001]
  • [Cites] Nature. 2003 Apr 24;422(6934):835-47 [12695777.001]
  • [Cites] J Immunol Methods. 2006 Apr 20;311(1-2):130-8 [16527301.001]
  • [Cites] Am J Clin Pathol. 1991 Sep;96(3):300-5 [1877527.001]
  • [Cites] Urology. 1999 Apr;53(4):853-7 [10197874.001]
  • [Cites] Nat Protoc. 2007;2(9):2285-94 [17853885.001]
  • [Cites] Cytometry A. 2006 Jul;69(7):691-703 [16680709.001]
  • [Cites] Cytometry A. 2004 Jun;59(2):167-71 [15170595.001]
  • [Cites] Cell Oncol. 2004;26(1-2):73-9 [15371659.001]
  • [Cites] Cytometry A. 2004 Jun;59(2):210-9 [15170600.001]
  • [Cites] Endoscopy. 2006 Dec;38(12):1275-83 [17163333.001]
  • [Cites] Cytometry B Clin Cytom. 2003 May;53(1):20-5 [12717687.001]
  • [Cites] Anal Cell Pathol. 2003;25(2):51-62 [12632014.001]
  • [Cites] Science. 2001 May 18;292(5520):1401-3 [11360991.001]
  • [Cites] Cytometry B Clin Cytom. 2003 May;53(1):4-10 [12717685.001]
  • [Cites] Cytometry A. 2006 Mar;69(3):127-30 [16479595.001]
  • [Cites] Cytometry. 1991;12(5):381-7 [1935453.001]
  • [Cites] Laryngorhinootologie. 1999 Mar;78(3):131-8 [10226980.001]
  • [Cites] Cytometry A. 2007 Dec;71(12):1003-10 [17972305.001]
  • [Cites] Cytometry. 1999 Aug 15;38(4):176-83 [10440855.001]
  • [Cites] J Immunol Methods. 2000 Dec 1;246(1-2):175-85 [11121558.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Cytometry. 1998 Aug 15;34(4):159-79 [9725457.001]
  • [Cites] Comput Med Imaging Graph. 1998 Mar-Apr;22(2):89-102 [9719850.001]
  • [Cites] Cytometry A. 2006 Aug 1;69(8):872-9 [16969808.001]
  • [Cites] Onkologie. 2002 Feb;25(1):40-6 [11893882.001]
  • [Cites] Cancer. 2003 Oct 25;99(5):263-71 [14579292.001]
  • [Cites] Anal Cell Pathol. 2003;25(4):159-66 [14501082.001]
  • [Cites] J Biomed Opt. 2006 Jan-Feb;11(1):014019 [16526896.001]
  • [Cites] Nat Rev Immunol. 2007 Nov;7(11):897-904 [17917673.001]
  • [Cites] Ophthalmol Clin North Am. 2004 Mar;17(1):21-31 [15102511.001]
  • [Cites] Nat Med. 2001 Feb;7(2):245-8 [11175858.001]
  • [Cites] Nat Rev Immunol. 2004 Aug;4(8):648-55 [15286731.001]
  • [Cites] Exp Cell Res. 2005 Apr 1;304(2):604-19 [15748904.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):050504 [17994860.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):445-52 [15770781.001]
  • [Cites] Ann N Y Acad Sci. 1993 Mar 20;677:233-51 [8494212.001]
  • [Cites] Am J Pathol. 2004 Mar;164(3):831-40 [14982837.001]
  • [Cites] Cytometry A. 2006 Aug 1;69(8):852-62 [16969805.001]
  • [Cites] Cytometry A. 2006 Mar;69(3):135-8 [16479598.001]
  • [Cites] Pigment Cell Res. 2001 Feb;14(1):2-8 [11277490.001]
  • [Cites] Exp Cell Res. 1955;(Suppl 3):40-51 [13344460.001]
  • [Cites] Lab Chip. 2006 Aug;6(8):995-1000 [16874368.001]
  • [Cites] Clin Exp Allergy. 2004 Jan;34(1):65-70 [14720264.001]
  • [Cites] Oncol Rep. 2005 May;13(5):915-22 [15809758.001]
  • [Cites] Cytometry A. 2005 Apr;64(2):62-71 [15729713.001]
  • [Cites] Cytometry A. 2008 Mar;73(3):209-19 [18044751.001]
  • [Cites] Mol Med. 1999 Dec;5(12):785-94 [10666478.001]
  • [Cites] Cell Prolif. 2005 Aug;38(4):171-4 [16098176.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):914-6 [16900128.001]
  • [Cites] Adv Biochem Eng Biotechnol. 2003;83:189-209 [12934931.001]
  • [Cites] Cytometry A. 2006 Jul;69(7):582-7 [16807892.001]
  • (PMID = 18351309.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome
  • [Number-of-references] 60
  •  go-up   go-down


17. Kouzu Y, Uzawa K, Koike H, Saito K, Nakashima D, Higo M, Endo Y, Kasamatsu A, Shiiba M, Bukawa H, Yokoe H, Tanzawa H: Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer; 2006 Mar 13;94(5):717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis.
  • Furthermore, we found a statistical correlation between the protein expression status and disease-free survival (P=0.029).
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Mouth Neoplasms / genetics. Stathmin / biosynthesis
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Keratinocytes / physiology. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Up-Regulation

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1993 Oct;8(10):2869-72 [8397372.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):21004-10 [1939149.001]
  • [Cites] Prostate. 1995 Aug;27(2):102-9 [7638082.001]
  • [Cites] Cell. 1996 Feb 23;84(4):623-31 [8598048.001]
  • [Cites] Biotechnol Genet Eng Rev. 1996;13:19-50 [8948108.001]
  • [Cites] Cell Signal. 1997 May-Jun;9(3-4):249-55 [9218124.001]
  • [Cites] Br J Cancer. 1998 Sep;78(6):701-9 [9743287.001]
  • [Cites] J Clin Oncol. 2005 Jan 10;23(2):346-56 [15637397.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1915-21 [15870709.001]
  • [Cites] Int J Oncol. 2005 Jul;27(1):59-67 [15942644.001]
  • [Cites] Int J Mol Med. 2005 Aug;16(2):269-73 [16012760.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):704-13 [16094606.001]
  • [Cites] Mol Carcinog. 2000 Mar;27(3):158-65 [10708477.001]
  • [Cites] FEBS Lett. 2000 Mar 10;469(2-3):155-8 [10713262.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1202-9 [10786892.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):837-46 [10866210.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3537-41 [10910066.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):311-8 [10917544.001]
  • [Cites] Anal Biochem. 2000 Aug 15;284(1):49-59 [10933855.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3949-56 [11051243.001]
  • [Cites] Cancer Invest. 2000;18(8):722-30 [11107442.001]
  • [Cites] Curr Opin Mol Ther. 2000 Dec;2(6):633-42 [11249740.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] Cancer. 2001 Apr 15;91(8):1494-9 [11301397.001]
  • [Cites] Mt Sinai J Med. 2002 Oct;69(5):299-304 [12415323.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6598-605 [12438255.001]
  • [Cites] J Dent Res. 2003 Aug;82(8):607-11 [12885844.001]
  • [Cites] Int J Cancer. 2004 Jun 10;110(2):225-31 [15069686.001]
  • [Cites] J Cell Biochem. 2004 Oct 1;93(2):242-50 [15368352.001]
  • [Cites] J Biol Chem. 1983 Sep 10;258(17):10786-93 [6577004.001]
  • [Cites] J Biol Chem. 1988 Sep 15;263(26):12813-5 [3417633.001]
  • [Cites] Leukemia. 1993 Oct;7(10):1538-46 [8412315.001]
  • (PMID = 16495930.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / STMN1 protein, human; 0 / Stathmin
  • [Other-IDs] NLM/ PMC2361217
  •  go-up   go-down


18. Ge G, Wong GW: Classification of premalignant pancreatic cancer mass-spectrometry data using decision tree ensembles. BMC Bioinformatics; 2008;9:275
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Biomarkers, Tumor / analysis. Decision Support Techniques. Mass Spectrometry / methods. Neoplasm Proteins / analysis. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism
  • [MeSH-minor] Algorithms. Diagnosis, Computer-Assisted / methods. Gene Expression Profiling / methods. Humans. Prognosis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2007 Apr;7(8):1345-55 [17443640.001]
  • [Cites] J Theor Biol. 2006 Oct 21;242(4):941-6 [16806277.001]
  • [Cites] Genome Inform. 2006;17(2):194-205 [17503392.001]
  • [Cites] Recent Results Cancer Res. 2007;176:89-120 [17607919.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] IEEE Trans Biomed Eng. 2000 Sep;47(9):1271-80 [11008429.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Biotechniques. 2002 Mar;Suppl:34-8, 40-1 [11906005.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] Bioinformatics. 2003 Sep 1;19(13):1636-43 [12967959.001]
  • [Cites] Proteomics. 2003 Sep;3(9):1667-72 [12973722.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):437-50 [14706336.001]
  • [Cites] Proteomics. 2004 Feb;4(2):442-7 [14760715.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Proteomics. 2004 Mar;4(3):766-83 [14997498.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):367-78 [14990683.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] BMC Bioinformatics. 2004 Mar 11;5:26 [15113409.001]
  • [Cites] Endocr Relat Cancer. 2004 Jun;11(2):163-78 [15163296.001]
  • [Cites] Ann N Y Acad Sci. 2004 May;1020:154-74 [15208191.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):238-44 [15231857.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):636-41 [15234244.001]
  • [Cites] Proteomics. 2004 Aug;4(8):2476-95 [15274142.001]
  • [Cites] Urol Oncol. 2004 Jul-Aug;22(4):322-8 [15283891.001]
  • [Cites] BMC Bioinformatics. 2005;6:68 [15788095.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2200-9 [15784749.001]
  • [Cites] J Biotechnol. 2007 Jan 10;127(3):417-24 [17045354.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):54-64 [16819514.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):849-55 [17332923.001]
  • [Cites] Curr Opin Oncol. 2004 Sep;16(5):478-84 [15314519.001]
  • [Cites] Surg Oncol Clin N Am. 2004 Oct;13(4):751-60, xi [15350946.001]
  • [Cites] Artif Intell Med. 2004 Oct;32(2):71-83 [15364092.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1302-5 [15371828.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1042-55 [15473694.001]
  • [Cites] Clin Chem. 2004 Oct;50(10):1939-42 [15484332.001]
  • [Cites] Clin Chem. 1982 Jun;28(6):1346-8 [7074944.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):307-9 [15713966.001]
  • [Cites] Bioinformatics. 2005 Jun;21 Suppl 1:i487-94 [15961495.001]
  • [Cites] Bioinformatics. 2005 Jul 15;21(14):3138-45 [15890743.001]
  • [Cites] Methods Mol Med. 2005;103:189-97 [15542907.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1454-63 [16285947.001]
  • [Cites] J Theor Biol. 2006 Jan 7;238(1):172-6 [16043193.001]
  • [Cites] Proteomics. 2006 Jan;6(2):592-604 [16342141.001]
  • [Cites] Am J Gastroenterol. 2006 May;101(5):965-6 [16696782.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1670-8 [16697731.001]
  • [Cites] Proteomics. 2006 Jul;6(13):3871-9 [16739137.001]
  • [Cites] Proteomics. 2007 May;7(10):1644-53 [17443844.001]
  • (PMID = 18547427.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2440392
  •  go-up   go-down


19. Motokura T, Nakamura Y, Sato H: Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies. BMC Cancer; 2007;7:217
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies.
  • In contrast to epithelial tumors, methylation status of the 14-3-3sigma gene was not associated with expression in hematological malignancies.
  • The expression levels of 14-3-3sigma, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth.
  • This is the first report of aberrant 14-3-3sigma expression in non-epithelial tumors in vivo.
  • Since the significance of 14-3-3sigma overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3sigma gene in non-epithelial as well as epithelial tumors is warranted.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Exonucleases / biosynthesis. Hematologic Neoplasms / genetics. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] 14-3-3 Proteins. ADP-Ribosylation Factors / genetics. Base Sequence. Blotting, Western. Cell Cycle. DNA Methylation. Exoribonucleases. Gene Expression Regulation, Neoplastic / genetics. Genes, p16. Humans. Polymorphism, Single-Stranded Conformational / genetics. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / genetics. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1760-9 [10557050.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):61-72 [16797759.001]
  • [Cites] J Cell Biol. 2000 May 29;149(5):1117-30 [10831615.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45201-6 [11574543.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1411-8 [11830494.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2072-6 [11929827.001]
  • [Cites] Oncogene. 2002 Apr 4;21(15):2418-24 [11948426.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):871-5 [12075357.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3043-9 [12082535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):165-9 [12582028.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):161-6 [14568170.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):329-42 [15167810.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1575-85 [15073049.001]
  • [Cites] Anal Biochem. 1988 Apr;170(1):203-8 [3389511.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):507-13 [1390337.001]
  • [Cites] Lab Invest. 1993 Mar;68(3):361-6 [8450652.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 1997 Feb 1;89(3):965-74 [9028328.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Leukemia. 1998 Jun;12(6):845-59 [9639410.001]
  • [Cites] Leuk Res. 1998 May;22(5):413-20 [9652727.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):616-20 [10524633.001]
  • [Cites] Amino Acids. 2005 Mar;28(2):199-205 [15723242.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):707-15 [16271083.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2448-54 [16353156.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3248-55 [16540677.001]
  • [Cites] Cancer Lett. 2006 May 8;236(1):105-14 [15979784.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • (PMID = 18036248.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 3.6.5.2 / ADP-Ribosylation Factors
  • [Other-IDs] NLM/ PMC2222637
  •  go-up   go-down


20. Kamiya M, Kobayashi H, Hama Y, Koyama Y, Bernardo M, Nagano T, Choyke PL, Urano Y: An enzymatically activated fluorescence probe for targeted tumor imaging. J Am Chem Soc; 2007 Apr 4;129(13):3918-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An enzymatically activated fluorescence probe for targeted tumor imaging.
  • We used a mouse tumor model to assess the practical utility of AM-TG-betaGal, after confirming that tumors in the model could be labeled with an avidin-beta-galactosidase conjugate.
  • This conjugate was administered to the mice in vivo, followed by AM-TG-betaGal, and subsequent ex vivo fluorescence imaging clearly visualized intraperitoneal tumors as small as 200 microm.
  • This strategy has potential clinical application, for example, in video-assisted laparoscopic tumor resection.
  • [MeSH-major] Esterases / metabolism. Fluorescent Dyes / chemistry. Fluorescent Dyes / metabolism. Neoplasms / enzymology. Neoplasms / pathology. beta-Galactosidase / metabolism
  • [MeSH-minor] Animals. Cell Line. Humans. Mice. Molecular Structure. Neoplasm Transplantation. Oxidation-Reduction. Swine

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Methods. 2006 Apr;3(4):295-301 [16554835.001]
  • [Cites] J Am Chem Soc. 2005 Apr 6;127(13):4888-94 [15796553.001]
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):321-5 [10700150.001]
  • [Cites] Lett Appl Microbiol. 2000 Apr;30(4):336-40 [10792658.001]
  • [Cites] J Am Chem Soc. 2001 Mar 21;123(11):2530-6 [11456921.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3606-12 [11705883.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Dec 31;53(3):247-64 [11744170.001]
  • [Cites] J Appl Microbiol. 2001 Dec;91(6):1118-30 [11851821.001]
  • [Cites] Nucl Med Biol. 2003 Apr;30(3):261-5 [12745017.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3756-62 [14506168.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1579-83 [14996712.001]
  • [Cites] J Immunol Methods. 1982 Nov 12;54(3):297-307 [6816855.001]
  • [Cites] Anal Biochem. 1985 Apr;146(1):211-9 [3922243.001]
  • [Cites] J Immunol Methods. 1985 Nov 7;83(2):317-25 [2414365.001]
  • [Cites] EMBO J. 1986 Dec 1;5(12):3133-42 [3102226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(8):2603-7 [3128790.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4842-6 [3387440.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):8171-8 [2498308.001]
  • [Cites] Nature. 1989 Jul 20;340(6230):245-6 [2547163.001]
  • [Cites] Cytometry. 1991;12(4):291-301 [1905992.001]
  • [Cites] Exp Parasitol. 1991 Nov;73(4):440-50 [1959571.001]
  • [Cites] Anal Biochem. 1991 Dec;199(2):238-42 [1725950.001]
  • [Cites] Dev Biol. 1994 Jan;161(1):77-83 [8293887.001]
  • [Cites] Anal Biochem. 1993 Nov 15;215(1):24-30 [8297011.001]
  • [Cites] Zentralbl Bakteriol. 1994 Mar;280(4):476-87 [8061408.001]
  • [Cites] Trends Genet. 1994 Aug;10(8):286-92 [7940758.001]
  • [Cites] Cytometry. 1994 Nov 1;17(3):216-23 [7851157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10315-20 [8816797.001]
  • [Cites] Science. 1998 Jan 2;279(5347):84-8 [9417030.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):25-9 [9428779.001]
  • [Cites] Anal Biochem. 1998 Mar 15;257(2):234-7 [9514778.001]
  • [Cites] Anal Biochem. 1999 Aug 15;273(1):41-8 [10452797.001]
  • [Cites] Proc Natl Acad Sci U S A. 1963 Jul;50:1-6 [13975398.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):607-12 [16867223.001]
  • (PMID = 17352471.001).
  • [ISSN] 0002-7863
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 BC010657-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; EC 3.1.- / Esterases; EC 3.2.1.23 / beta-Galactosidase
  • [Other-IDs] NLM/ NIHMS61920; NLM/ PMC2555972
  •  go-up   go-down


21. Knowlton N, Dozmorov I, Kyker KD, Saban R, Cadwell C, Centola MB, Hurst RE: Template-driven gene selection procedure. Syst Biol (Stevenage); 2006 Jan;153(1):4-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This approach is based on template matching in which the interaction of the variables of inherent malignancy and the ability to express the malignant phenotype are modelled.
  • Immortalised normal urothelial cells and bladder cancer cells of different malignancy were grown in conventional two-dimensional tissue culture and in three dimensions on extracellular matrices (ECMs) that were either permissive or restrictive for expression of the malignant phenotype.
  • By assigning values to each of the biological variables of inherent malignancy and the ability to express the malignant phenotype, a template was constructed, which encapsulated the interaction between them.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2004;32(19):e147 [15514108.001]
  • [Cites] J Biol Chem. 2004 Oct 22;279(43):44667-72 [15302871.001]
  • [Cites] J Immunol. 2004 Jun 1;172(11):7200-5 [15153545.001]
  • [Cites] Br J Cancer. 1977 Feb;35(2):142-51 [836756.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6372-80 [1933900.001]
  • [Cites] J Urol. 1994 May;151(5):1198-201 [8158759.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 [14500831.001]
  • [Cites] Nucleic Acids Res. 2005;33(3):864-72 [15701758.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):171-8 [15308542.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Oct;20(5):437-42 [9801762.001]
  • [Cites] Biochim Biophys Acta. 1996 Dec 11;1309(3):183-8 [8982252.001]
  • [Cites] J Urol. 1995 Oct;154(4):1532-8 [7658585.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Sep;120(9):943-7 [8074821.001]
  • [Cites] BMC Bioinformatics. 2004 May 5;5:53 [15128432.001]
  • [Cites] Trends Mol Med. 2003 Jan;9(1):5-10 [12524204.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):90-6 [12469123.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6973-80 [12460915.001]
  • [Cites] Nat Biotechnol. 2004 May;22(5):615-21 [15122300.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5346-57 [14614020.001]
  • [Cites] Urol Oncol. 2003 Jul-Aug;21(4):255-61 [12954494.001]
  • [Cites] OMICS. 2003 Fall;7(3):235-52 [14583114.001]
  • [Cites] Anticancer Res. 2003 Jul-Aug;23(4):3119-28 [12926044.001]
  • [Cites] J Urol. 2003 Mar;169(3):1122-33 [12576866.001]
  • [Cites] J Biochem Biophys Methods. 2003 Jan 31;55(1):53-66 [12559588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):262-7 [10618406.001]
  • [Cites] J Urol. 2000 Mar;163(3):1033-8 [10688044.001]
  • [Cites] Anticancer Res. 2000 Nov-Dec;20(6B):4579-83 [11205307.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2492-9 [11289120.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1957-62 [11448910.001]
  • [Cites] Genome Biol. 2001;2(10):RESEARCH0042 [11597334.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):464-70 [11839665.001]
  • [Cites] Genome Res. 2002 Nov;12(11):1703-15 [12421757.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:509-14 [12454646.001]
  • (PMID = 16983830.001).
  • [ISSN] 1741-2471
  • [Journal-full-title] Systems biology
  • [ISO-abbreviation] Syst Biol (Stevenage)
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE796
  • [Grant] United States / NCRR NIH HHS / RR / P20 RR017703; United States / NCI NIH HHS / CA / R01 CA075322; United States / NIDDK NIH HHS / DK / R01 DK069808; United States / NCI NIH HHS / CA / CA75322; United States / NCRR NIH HHS / RR / P20 RR1557; United States / NCRR NIH HHS / RR / P20 RR016478
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS12540; NLM/ PMC1618795
  •  go-up   go-down


22. Murad-Regadas SM, Regadas FS, Rodrigues LV, Barreto RG, Monteiro FC, Landim BB, Holanda EC: Role of three-dimensional anorectal ultrasonography in the assessment of rectal cancer after neoadjuvant radiochemotherapy: preliminary results. Surg Endosc; 2009 Jun;23(6):1286-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Three-dimensional anorectal ultrasound (3-DAUS) scanning provides accurate information on tumor size and its relation to the anal muscles.
  • The patients were grouped according to the distance (cm) between the distal tumor edge and the proximal border of the internal anal sphincter (IAS) (group I, presenting anal canal invasion; group II, < or =2.0 cm; group III, >2.0 cm).
  • RESULTS: Four (16%) patients (three in group I, one in group II) experienced complete tumor regression.
  • Fourteen (56%) tumors (six in group I, seven in group II, and one in group III) regressed partially.
  • 3-DAUS and pathological findings were concordant in 24 (96%) patients, with only one (4%) nonconclusive post-RCT 3-DAUS result found to be a residual tumor.
  • Tumor regression made sphincter-saving surgery possible in 13 patients (eight in group III, four complete tumor regression, and one nonconclusive on 3-DAUS).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Endosonography / methods. Imaging, Three-Dimensional / methods. Rectal Neoplasms / diagnostic imaging
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging / methods. Prospective Studies. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1999 Feb;42(2):159-66 [10211490.001]
  • [Cites] Dis Colon Rectum. 1992 Apr;35(4):362-8 [1582359.001]
  • [Cites] Surg Endosc. 2000 Nov;14 (11):1005-9 [11116406.001]
  • [Cites] Surg Endosc. 2007 Dec;21(12 ):2207-11 [17479327.001]
  • [Cites] Surg Endosc. 2002 Sep;16(9):1280-5 [11988797.001]
  • [Cites] Dis Colon Rectum. 1996 Jan;39(1):45-9 [8601356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 1;31(3):553-9 [7852119.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):528-35 [14751524.001]
  • [Cites] Biomed Pharmacother. 2004 Oct;58(8):451-7 [15464875.001]
  • [Cites] Eur Radiol. 2005 Aug;15(8):1658-66 [15806369.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):455-61 [17139456.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):109-12 [14687151.001]
  • [Cites] Dis Colon Rectum. 1997 Feb;40(2):140-4 [9075746.001]
  • [Cites] Br J Surg. 1991 Jul;78(7):785-8 [1873701.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1047-53 [16865595.001]
  • [Cites] Dis Colon Rectum. 1985 Jan;28(1):42-6 [3882360.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1075-83 [10950005.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1051-6 [12195189.001]
  • [Cites] Surg Endosc. 1999 Oct;13(10 ):980-4 [10526031.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1087-96 [9749491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1043-7 [10192353.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):735-9 [10954459.001]
  • (PMID = 18813985.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


23. Mistrangelo M, Mobiglia A, Cassoni P, Castellano I, Maass J, Martina MC, Bellò M, Mussa A: [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases]. Suppl Tumori; 2005 May-Jun;4(3):S29-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous carcinoma of the anus or Buschke-Lowenstein tumor of the anus: staging and treatment. Report of 3 cases].
  • [Transliterated title] Il carcinoma verrucoso dell'ano o tumore di buschke-lowenstein dell'ano: stadiazione e trattamento presentazione di 3 casi.
  • INTRODUCTION: Giant condyloma acuminatum or Buschke Lowenstein tumor of the anorectal and perianal regions is an uncommon entity that commonly affects genitalia.
  • The hallmark of the disease is the high rate of recurrence (66%) and malignant transformation (56%).
  • MATERIALS AND METHODS: At the Oncological Surgical Department, University of Turin, three patients were diagnosed with a Buschke Lowenstein tumor.
  • In one case we observed a late anal stenosis treated with local dilatations.
  • One patient with a small persistence of the disease was treated with cryotherapy.
  • All inguinal nodes revealed negative to definitive histological exam, that confirmed the diagnosis of Buschke Lowenstein tumor of the primary lesion.
  • CONCLUSIONS: Buschke Lowenstein tumors are rare but extensive lesions difficult to treat.
  • [MeSH-major] Anus Neoplasms / pathology. Anus Neoplasms / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery
  • [MeSH-minor] Adult. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Buschke Lowenstein Tumor.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16437884.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


24. Prasad K, Zimmermann B, Prabhu G, Pai M: Datamining approach for automation of diagnosis of breast cancer in immunohistochemically stained tissue microarray images. Open Med Inform J; 2010;4:86-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Datamining approach for automation of diagnosis of breast cancer in immunohistochemically stained tissue microarray images.
  • Cancer of the breast is the second most common human neoplasm, accounting for approximately one quarter of all cancers in females after cervical carcinoma.
  • Estrogen receptor (ER), Progesteron receptor and human epidermal growth factor receptor (HER-2/neu) expressions play an important role in diagnosis and prognosis of breast carcinoma.
  • TMA technique is widely used to evaluate hormone expression for diagnosis of breast cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1989 Mar 1;63(5):863-72 [2644015.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jun;34(3):221-8 [7579486.001]
  • [Cites] Pathol Int. 2003 Oct;53(10):693-9 [14516320.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1449-56 [14507652.001]
  • [Cites] Pathol Res Pract. 1992 Jun;188(4-5):478-83 [1409075.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):492-4 [12683883.001]
  • [Cites] Mod Pathol. 2002 Dec;15(12):1374-80 [12481020.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1557-65 [12414504.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):417-27 [11331959.001]
  • [Cites] Clin Exp Allergy. 2001 Mar;31(3):504-8 [11260164.001]
  • [Cites] Lab Invest. 2000 Dec;80(12):1943-9 [11140706.001]
  • [Cites] Circulation. 1999 Jun 1;99(21):2750-6 [10351968.001]
  • [Cites] Br J Cancer. 1989 Aug;60(2):252-7 [2765376.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):7057-61 [2208173.001]
  • [Cites] Cancer Res. 1986 Aug;46(8 Suppl):4256s-4264s [2425944.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D871-7 [17989087.001]
  • [Cites] Curr Opin Biotechnol. 2007 Aug;18(4):318-25 [17643281.001]
  • [Cites] J Microsc. 2007 Jun;226(Pt 3):244-55 [17535263.001]
  • [Cites] BMC Bioinformatics. 2007;8:81 [17343750.001]
  • [Cites] Diagn Pathol. 2006;1:36 [17034635.001]
  • [Cites] Breast Cancer Res. 2005;7(5):R598-604 [16168103.001]
  • [Cites] Indian J Cancer. 2005 Jan-Mar;42(1):9-14 [15805686.001]
  • [Cites] J Biopharm Stat. 2004 Aug;14(3):671-85 [15468758.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Jul;4(4):421-3 [15225087.001]
  • [Cites] Mol Cancer Res. 2004 Apr;2(4):215-24 [15140943.001]
  • [Cites] Am J Transplant. 2004 Feb;4(2):248-56 [14974947.001]
  • [Cites] Pathol Res Pract. 1993 Sep;189(8):862-6 [8302707.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):158-62 [8042582.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S9-12 [7942615.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Aug;15(4):274-80 [8397648.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2514-9 [8640700.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1559-65 [9358857.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Pathol. 1990 Apr;160(4):295-303 [2162939.001]
  • [Cites] Am J Clin Pathol. 1992 Jul;98(1):105-11 [1615913.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):876-8 [7490328.001]
  • (PMID = 21589855.001).
  • [ISSN] 1874-4311
  • [Journal-full-title] The open medical informatics journal
  • [ISO-abbreviation] Open Med Inform J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC3095117
  • [Keywords] NOTNLM ; Automated breast cancer diagnosis / Decision support systems / Image analysis / Tissue microarray / staining expression quantification.
  •  go-up   go-down


25. Ghosh G, Lee AG, Palecek SP: Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates. Anal Biochem; 2009 Oct 15;393(2):205-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidermal growth factor receptor (EGFR) signaling plays an important role in a majority of solid tumors, and therapeutics targeted against EGFR has demonstrated promise in slowing growth of these tumors.

  • Hazardous Substances Data Bank. POLYACRYLAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Dec 27;19(56):6550-65 [11426640.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):905-12 [10953014.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S3-8 [11597398.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] Hum Antibodies. 2001;10(3-4):143-7 [11847425.001]
  • [Cites] Anticancer Res. 2001 Sep-Oct;21(5):3413-8 [11848502.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):310-5 [11857424.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:2-8 [12202782.001]
  • [Cites] Oncologist. 2002;7 Suppl 4:31-9 [12202786.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Oncologist. 2003;8(6):531-8 [14657531.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):28-32 [14679115.001]
  • [Cites] Cancer Treat Rev. 2004 Feb;30(1):1-17 [14766123.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Anal Biochem. 2004 Jun 15;329(2):180-9 [15158476.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):618-35 [15234243.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5814-28 [7689153.001]
  • [Cites] J Cell Biol. 1997 Feb 24;136(4):811-21 [9049247.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5498-504 [9407958.001]
  • [Cites] J Cell Biol. 1998 Mar 9;140(5):1055-62 [9490719.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2405-14 [9815641.001]
  • [Cites] N Engl J Med. 2005 Feb 24;352(8):786-92 [15728811.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2879-82 [15837736.001]
  • [Cites] PLoS Med. 2005 Mar;2(3):e73 [15737014.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7096-101 [16103058.001]
  • [Cites] Biomacromolecules. 2005 Sep-Oct;6(5):2765-75 [16153117.001]
  • [Cites] Nat Clin Pract Oncol. 2006 Jan;3(1):50-7; quiz 1 p following 57 [16407879.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6 [18309959.001]
  • [Cites] J Biol Chem. 2000 Feb 4;275(5):3288-95 [10652316.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):603-7 [10767376.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1850-5 [11448895.001]
  • (PMID = 19583965.001).
  • [ISSN] 1096-0309
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM074691; United States / NIGMS NIH HHS / GM / R01 GM074691-04; United States / NIGMS NIH HHS / GM / R01 GM 074691
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Adaptor Proteins, Signal Transducing; 0 / Calcium-Binding Proteins; 0 / EPS15 protein, human; 0 / Hydrogels; 0 / Immobilized Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 0 / Recombinant Fusion Proteins; 9003-05-8 / polyacrylamide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ NIHMS136420; NLM/ PMC2758617
  •  go-up   go-down


26. Sheng SL, Bao SH, Huang G, Wang LM: Development of time-resolved immunofluorometric assays for vascular endothelial growth factor and application on plasma of patients with gastric tumours. Clin Exp Immunol; 2008 Mar;151(3):459-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasma VEGF concentrations were measured by TR-IFMA in 92 healthy controls, in 36 benign stomach disease patients and in 92 gastric cancer patients before surgery.
  • VEGF levels were associated significantly with the presence of distant metastases, as well as invasion depth of the tumour and tumour stage, but not with tumour location, tumour histology, differentiation or the presence of lymph node metastases.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Stomach Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Enzyme-Linked Immunosorbent Assay. Female. Fluoroimmunoassay / methods. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Proteins / blood. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1998 Dec;34(13):2041-5 [10070308.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2187-90 [9815613.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):12-21 [16139825.001]
  • [Cites] Clin Chim Acta. 2007 May 1;380(1-2):106-11 [17321510.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1004-8 [10737380.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • [Cites] Circulation. 2000 Jul 11;102(2):185-90 [10889129.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):242-8 [11001067.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):657-62 [11078612.001]
  • [Cites] Ann Surg. 2002 Jul;236(1):37-42 [12131083.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Nov;17(11):1165-9 [12453275.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):97-103 [12507965.001]
  • [Cites] Cancer Lett. 2003 Mar 31;192(2):215-25 [12668286.001]
  • [Cites] Oncol Rep. 2004 Feb;11(2):435-9 [14719080.001]
  • [Cites] Steroids. 2004 Jul;69(7):461-71 [15246776.001]
  • [Cites] Clin Chem. 1983 Jan;29(1):65-8 [6336682.001]
  • [Cites] Nature. 1983 Jan 20;301(5897):258-60 [6337344.001]
  • [Cites] Anal Biochem. 1984 Mar;137(2):335-43 [6375455.001]
  • [Cites] Clin Chem. 1987 Nov;33(11):1994-9 [3119252.001]
  • [Cites] Clin Biochem. 1988 Jun;21(3):139-50 [3292080.001]
  • [Cites] Clin Chem. 1990 Aug;36(8 Pt 1):1497-502 [1696856.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] J Cell Biochem. 1991 Nov;47(3):211-8 [1791185.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Am J Pathol. 1995 May;146(5):1029-39 [7538264.001]
  • [Cites] Pharmacol Ther. 1995 May;66(2):207-35 [7667396.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):663-8 [9012841.001]
  • [Cites] Ann Clin Biochem. 1997 May;34 ( Pt 3):276-80 [9158825.001]
  • [Cites] J Immunol Methods. 1998 Oct 1;219(1-2):45-55 [9831387.001]
  • [Cites] Ann Oncol. 1999 Aug;10(8):965-71 [10509160.001]
  • (PMID = 18234057.001).
  • [ISSN] 1365-2249
  • [Journal-full-title] Clinical and experimental immunology
  • [ISO-abbreviation] Clin. Exp. Immunol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2276956
  •  go-up   go-down


27. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML, Olivi A, Judy K, Tatter SB, Dolan ME: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol; 2007 Feb 1;25(4):399-404
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial.
  • PURPOSE: This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safety of extending continuous-infusion O6-BG at the optimal dose with intracranially implanted carmustine wafers, and (3) measure the pharmacokinetics of O6-BG and its metabolite.
  • Tumor samples were evaluated for AGT levels.
  • Future trials are required to determine if the inhibition of tumor AGT levels results in increased efficacy.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GUANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3025-31 [10955780.001]
  • [Cites] J Clin Oncol. 1998 Nov;16(11):3570-5 [9817277.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7178-87 [16192602.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6307-10 [11103789.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2277-83 [11980998.001]
  • [Cites] Neuro Oncol. 2003 Apr;5(2):79-88 [12672279.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1845-9 [12721262.001]
  • [Cites] Neuro Oncol. 2004 Jan;6(1):28-32 [14769137.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1871-4 [15041700.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jul;87(14):5368-72 [2164681.001]
  • [Cites] Cancer Commun. 1990;2(11):371-7 [2242301.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):441-6 [1993909.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3367-72 [1647266.001]
  • [Cites] J Neurosurg. 1992 Apr;76(4):640-7 [1545259.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(6):471-6 [8258196.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5123-30 [7923129.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 [7659775.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):783-8 [8631014.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):1030-6 [8855970.001]
  • [Cites] Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 [9218294.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1803-10 [9586894.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3522-8 [11032594.001]
  • (PMID = 17264335.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA14599; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / U01 CA062475; United States / NCRR NIH HHS / RR / M01 RR000055; United States / NCI NIH HHS / CA / U01 CA069852-12; United States / NCRR NIH HHS / RR / M01 RR000055-400764; United States / NCI NIH HHS / CA / CA69852; United States / NCRR NIH HHS / RR / RR000055-400764; United States / NCI NIH HHS / CA / CA069852-12; United States / NCI NIH HHS / CA / P30 CA014599-289015; United States / NCI NIH HHS / CA / CA62475; United States / NCI NIH HHS / CA / U01 CA069852; United States / NCI NIH HHS / CA / CA014599-289015
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / carmustine with prolifeprosan 20; 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; U68WG3173Y / Carmustine
  • [Other-IDs] NLM/ NIHMS66419; NLM/ PMC2556256
  •  go-up   go-down


28. Zheng MH, Feng B, Hu CY, Lu AG, Wang ML, Li JW, Hu WG, Zang L, Mao ZH, Dong TT, Dong F, Cai W, Ma JJ, Zong YP, Li MK: Long-term outcome of laparoscopic total mesorectal excision for middle and low rectal cancer. Minim Invasive Ther Allied Technol; 2010 Dec;19(6):329-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local recurrence rates, the five-year disease-free survival rate and the five-year overall survival rate showed no difference between the two groups.
  • [MeSH-major] Digestive System Surgical Procedures / methods. Laparoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anal Canal / surgery. Disease-Free Survival. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091067.001).
  • [ISSN] 1365-2931
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


29. Bartusik D, Tomanek B, Lattová E, Perreault H, Fallone G: Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays. J Pharm Biomed Anal; 2010 Jan 5;51(1):192-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effective targeting of malignant cell surface antigens is essential in cancer therapy.
  • The study showed that incorporation of antibodies into targeted lipoplex results in more efficient delivery of the complex to tumor cells.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Breast Neoplasms / drug therapy. Drug Delivery Systems
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antigens, CD44 / immunology. Cell Line, Tumor. Cell Survival / drug effects. Chromatography, High Pressure Liquid / methods. DNA / administration & dosage. Drug Resistance, Neoplasm. Drug Synergism. Female. Humans. Hyaluronic Acid / administration & dosage. Lipids / administration & dosage. Magnetic Resonance Imaging / methods. Plasmids / administration & dosage. Receptor, ErbB-2 / immunology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Trastuzumab

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709839.001).
  • [ISSN] 1873-264X
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD44; 0 / Lipids; 0 / Lipofectamine; 9004-61-9 / Hyaluronic Acid; 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


30. Park JT, Chen X, Tropè CG, Davidson B, Shih IeM, Wang TL: Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin. Am J Pathol; 2010 Sep;177(3):1087-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amplification of the Notch3 locus has been detected in ovarian high-grade serous carcinoma (HGSC), the most common and malignant type of ovarian cancer.
  • Taken together, the above findings suggest that Notch3 pathway activation reprograms tumor cells to assume an array of embryonic stem cell markers and participates in development of chemoresistance in HGSC.
  • [MeSH-major] Carboplatin / therapeutic use. Cystadenocarcinoma, Serous / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism. Receptors, Notch / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cells, Cultured. Female. Humans. Immunohistochemistry. Middle Aged. Receptor, Notch3. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2009 May 7;28(18):1941-8 [19305429.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] PLoS One. 2010;5(6):e11198 [20585448.001]
  • [Cites] Anal Cell Pathol. 2001;23(3-4):107-28 [12082292.001]
  • [Cites] Cell. 2003 May 30;113(5):631-42 [12787504.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4144-9 [12874019.001]
  • [Cites] Cancer. 2004 May 15;100(10):2139-47 [15139056.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Reprod Med. 1994 Apr;39(4):241-8 [8040839.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):287-95 [15661210.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):487-91 [16186803.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):364-8 [17093407.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):814-9 [16844205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):228-38 [17167759.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):31-44 [17275076.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):749-57 [17429392.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4807-15 [17510410.001]
  • [Cites] Clin Cancer Res. 2007 Nov 15;13(22 Pt 1):6842-9 [17982121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6326-31 [18436640.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17635-51 [18441325.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8852-60 [18974129.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1407-15 [19190325.001]
  • [Cites] Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614 [19484149.001]
  • (PMID = 20671266.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA148826; United States / NCI NIH HHS / CA / R01-CA129080; United States / NCI NIH HHS / CA / R01-CA103937; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NOTCH3 protein, human; 0 / Receptor, Notch3; 0 / Receptors, Notch; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2928943
  •  go-up   go-down


31. Radulescu RT: Oncoprotein metastasis and its suppression revisited. J Exp Clin Cancer Res; 2010;29:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The past two decades have witnessed an increasing appreciation of the role of the tumor microenvironment, of genetic and epigenetic alterations in normal cells adjacent to tumors and of the migration of normal cells with aberrant intrinsic properties in cancer pathophysiology.
  • Aside from these insights, a novel concept termed "oncoprotein metastasis" (OPM) has recently been advanced and proposed to reflect protein-based neoplastic phenomena that might occur even before any modifications relating to the morphology, location or (epi)genetic outfit of cells during the malignant process.
  • Here, evidence is presented that supports the OPM perception and thus should contribute not only to further rethink the definition of a normal cell, but also the treatment of cancer disease in the years to come.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Neoplasms / pathology. Oncogene Proteins / metabolism
  • [MeSH-minor] Biophysics / methods. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Disease Progression. Epigenesis, Genetic. Humans. Loss of Heterozygosity. Neoplasm Metastasis. Peptides / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Jan 7;267(1):71-6 [10623576.001]
  • [Cites] J Biol Chem. 2010 Feb 26;285(9):6285-97 [20026604.001]
  • [Cites] J Endocrinol. 2000 Aug;166(2):R1-4 [10938588.001]
  • [Cites] Cell. 2003 Jan 10;112(1):1-2 [12526785.001]
  • [Cites] Cell. 2003 Jan 10;112(1):29-40 [12526791.001]
  • [Cites] Drugs Exp Clin Res. 2003;29(2):69-74 [12951836.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):473 [15057811.001]
  • [Cites] Nature. 1976 Mar 11;260(5547):170-3 [176594.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Cancer. 1982 Nov 15;50(10):2111-4 [6290023.001]
  • [Cites] Nature. 1983 Oct 27-Nov 2;305(5937):779-84 [6633649.001]
  • [Cites] N Engl J Med. 1987 Dec 17;317(25):1598-600 [3479684.001]
  • [Cites] Diabetes. 1990 Jun;39(6):683-9 [2161368.001]
  • [Cites] Trends Biochem Sci. 1992 Aug;17(8):312-5 [1412705.001]
  • [Cites] J Mol Recognit. 1992 Dec;5(4):132-7 [1339481.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10444-50 [8144628.001]
  • [Cites] Trends Biochem Sci. 1994 Jul;19(7):278 [7519375.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5296-300 [7923156.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):11831-5 [7991544.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):503-17 [7812921.001]
  • [Cites] Med Hypotheses. 1995 Jan;44(1):32-8 [7776899.001]
  • [Cites] Nature. 1995 Oct 19;377(6550):646-9 [7566179.001]
  • [Cites] J Endocrinol. 1995 Sep;146(3):365-8 [7595130.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2057-9 [8953032.001]
  • [Cites] N Engl J Med. 1997 May 29;336(22):1569-74 [9164814.001]
  • [Cites] Anal Quant Cytol Histol. 1998 Aug;20(4):313-20 [9739414.001]
  • [Cites] J Oral Pathol Med. 1999 Mar;28(3):97-101 [10069535.001]
  • [Cites] Trends Microbiol. 2005 Feb;13(2):79-85 [15680767.001]
  • [Cites] J Natl Compr Canc Netw. 2006 Jul;4(6):631-8 [16813730.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):782-6 [17429397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):E12 [18268316.001]
  • [Cites] PLoS Comput Biol. 2008 Mar;4(3):e1000011 [18369415.001]
  • [Cites] Cell. 2008 Jun 13;133(6):994-1005 [18555776.001]
  • [Cites] Science. 2008 Aug 22;321(5892):1086-8 [18719284.001]
  • [Cites] J Cell Biochem. 2008 Sep 1;105(1):81-8 [18452160.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1841-4 [18755941.001]
  • [Cites] Nature. 2009 Jan 1;457(7225):36-7 [19122629.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):274-84 [19308067.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Jul;10(7):478-87 [19546858.001]
  • [Cites] J Cell Physiol. 2009 Dec;221(3):766-70 [19688775.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17247-8 [19815521.001]
  • [Cites] Nat Rev Cancer. 2010 Feb;10(2):130-7 [20094047.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1460-1 [10995795.001]
  • (PMID = 20380702.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / Peptides
  • [Other-IDs] NLM/ PMC2855699
  •  go-up   go-down


32. Galanzha EI, Shashkov EV, Kelly T, Kim JW, Yang L, Zharov VP: In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells. Nat Nanotechnol; 2009 Dec;4(12):855-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo magnetic enrichment and multiplex photoacoustic detection of circulating tumour cells.
  • Detecting circulating tumour cells -- a common marker for the development of metastasis -- is difficult because ex vivo methods are not sensitive enough owing to limited blood sample volume and in vivo diagnosis is time-consuming as large volumes of blood must be analysed.
  • Here, we show a way to magnetically capture circulating tumour cells in the bloodstream of mice followed by rapid photoacoustic detection.
  • Magnetic nanoparticles, which were functionalized to target a receptor commonly found in breast cancer cells, bound and captured circulating tumour cells under a magnet.
  • By integrating in vivo multiplex targeting, magnetic enrichment, signal amplification and multicolour recognition, our approach allows circulating tumour cells to be concentrated from a large volume of blood in the vessels of tumour-bearing mice, and this could have potential for the early diagnosis of cancer and the prevention of metastasis in humans.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Opt. 2009 Mar-Apr;14(2):024007 [19405737.001]
  • [Cites] J Biomed Mater Res A. 2009 Jan;88(1):1-11 [18257079.001]
  • [Cites] Nat Nanotechnol. 2009 Oct;4(10):688-94 [19809462.001]
  • [Cites] Cancer Res. 2009 Oct 15;69(20):7926-34 [19826056.001]
  • [Cites] Clin Cancer Res. 2009 Jul 15;15(14):4722-32 [19584158.001]
  • [Cites] Anticancer Res. 2003 Mar-Apr;23(2A):1051-5 [12820346.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5044-7 [15289300.001]
  • [Cites] J Clin Lab Anal. 1999;13(5):229-33 [10494132.001]
  • [Cites] NMR Biomed. 2004 Nov;17(7):484-99 [15526347.001]
  • [Cites] Lab Chip. 2006 Jan;6(1):24-38 [16372066.001]
  • [Cites] Magn Reson Med. 2006 Jan;55(1):23-9 [16342157.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 May;132(5):287-92 [16432758.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2796-802 [16385568.001]
  • [Cites] Nature. 2006 May 25;441(7092):444-50 [16724056.001]
  • [Cites] Opt Lett. 2006 Jun 15;31(12):1827-9 [16729084.001]
  • [Cites] J Am Chem Soc. 2006 Jul 5;128(26):8378-9 [16802785.001]
  • [Cites] Nat Biotechnol. 2006 Jul;24(7):848-51 [16823374.001]
  • [Cites] Biomed Microdevices. 2006 Dec;8(4):299-308 [17003962.001]
  • [Cites] Opt Lett. 2006 Dec 15;31(24):3623-5 [17130924.001]
  • [Cites] Clin Cancer Res. 2007 Feb 1;13(3):920-8 [17289886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11760-5 [17601776.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2007 Aug;54(8):1642-7 [17703668.001]
  • [Cites] Nanomedicine (Lond). 2007 Apr;2(2):153-67 [17716118.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051503 [17994867.001]
  • [Cites] Nature. 2007 Dec 20;450(7173):1235-9 [18097410.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):698-703 [18182491.001]
  • [Cites] Nat Rev Cancer. 2008 May;8(5):329-40 [18404148.001]
  • [Cites] Gene Ther. 2008 Jun;15(12):902-10 [18418420.001]
  • [Cites] Nat Nanotechnol. 2008 Sep;3(9):557-62 [18772918.001]
  • [Cites] Cytometry A. 2008 Oct;73(10):884-94 [18677768.001]
  • [CommentIn] Nat Nanotechnol. 2009 Dec;4(12):798-9 [19966826.001]
  • (PMID = 19915570.001).
  • [ISSN] 1748-3395
  • [Journal-full-title] Nature nanotechnology
  • [ISO-abbreviation] Nat Nanotechnol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R21 EB005123-02; United States / NCI NIH HHS / CA / R21 CA139373-01; United States / NIBIB NIH HHS / EB / R21 EB0005123; United States / NCI NIH HHS / CA / CA133722; United States / NCI NIH HHS / CA / R01 CA133722; None / None / / R21 EB005123-02; United States / NIBIB NIH HHS / EB / R01 EB009230; United States / NCI NIH HHS / CA / R01 CA131164-02; United States / NIBIB NIH HHS / EB / R01 EB000873-02; None / None / / R01 CA131164-02; United States / NCI NIH HHS / CA / R01 CA133722-01; United States / NIBIB NIH HHS / EB / R21 EB005123; None / None / / R01 EB009230-02; None / None / / R21 CA139373-01; United States / NIBIB NIH HHS / EB / R01 EB000873; None / None / / R01 EB000873-02; United States / NIBIB NIH HHS / EB / R01 EB009230-02; United States / NCI NIH HHS / CA / R01 CA131164; United States / NCI NIH HHS / CA / R21 CA139373
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS370403; NLM/ PMC3663137
  •  go-up   go-down


33. Yoo HJ, Yun BR, Kwon JH, Ahn HS, Seol MA, Lee MJ, Yu GR, Yu HC, Hong B, Choi K, Kim DG: Genetic and expression alterations in association with the sarcomatous change of cholangiocarcinoma cells. Exp Mol Med; 2009 Feb 28;41(2):102-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we characterized a typical sarcomatoid phenotype of SCK, and classified the other cell lines according to tumor cell differentiation (a poorly differentiated JCK, a moderately differentiated Cho-CK, and a well differentiated Choi-CK cells), both morphologically and immunocytologically.
  • We further analyzed the genetic alterations of two tumor suppressor genes (p53 and FHIT) and the expression of Fas/FasL gene, well known CC-related receptor and its ligand, in these four CC cell lines.
  • [MeSH-minor] Acid Anhydride Hydrolases / genetics. Animals. Cell Line, Tumor. Female. Humans. Mice. Mice, Inbred BALB C. Mutation. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. Tumor Suppressor Protein p53 / genetics


34. Vaidya KS, Harihar S, Phadke PA, Stafford LJ, Hurst DR, Hicks DG, Casey G, DeWald DB, Welch DR: Breast cancer metastasis suppressor-1 differentially modulates growth factor signaling. J Biol Chem; 2008 Oct 17;283(42):28354-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • That metastatic tumor cells grow in selective non-native environments suggests an ability to differentially respond to local microenvironments.
  • BRMS1, like other metastasis suppressors, halts ectopic growth (metastasis) without blocking orthotopic tumor formation.
  • BRMS1-expressing tumor cells reach secondary sites but do not colonize distant tissues, compelling the hypothesis that BRMS1 selectively restricts the ability of tumor cells to respond to exogenous regulators in different tissues.
  • Specific modulation of signaling responses received from the microenvironment may ultimately dictate which environments are permissive/restrictive for tumor cell growth and provide insights into the biology underlying metastasis.

  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sci STKE. 2002 Sep 17;2002(150):re13 [12237449.001]
  • [Cites] Annu Rev Biochem. 2001;70:281-312 [11395409.001]
  • [Cites] J Biol Chem. 2003 Oct 10;278(41):39413-21 [12888567.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1562-9 [14581478.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Chem Biol. 2004 May;11(5):619-37 [15157873.001]
  • [Cites] Am J Surg Pathol. 1978 Sep;2(3):225-51 [210682.001]
  • [Cites] Nucleic Acids Res. 1987 Aug 11;15(15):5963-71 [3627975.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):272-306 [9174129.001]
  • [Cites] Oncogene. 1999 Aug 19;18(33):4756-66 [10467423.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):839-49 [15516957.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):713-7 [15705865.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3586-95 [15867352.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2764-9 [10850410.001]
  • [Cites] Clin Exp Metastasis. 2000;18(8):683-93 [11827072.001]
  • [Cites] Cell Death Differ. 2005 Jun;12(6):668-77 [15818404.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):305-11 [16012707.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] J Cell Sci. 2006 Apr 1;119(Pt 7):1307-19 [16537651.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] Mol Cell Biol. 2006 Dec;26(23):8683-96 [17000776.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6702-8 [17121889.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Oncogene. 2007 Feb 26;26(9):1338-45 [17322919.001]
  • [Cites] Lancet. 2007 May 19;369(9574):1742-57 [17512859.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1006-13 [17459054.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2007 Sep;12(2-3):175-90 [17587154.001]
  • [Cites] Am J Pathol. 2008 Mar;172(3):809-17 [18276787.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7438-44 [18211900.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Int J Mol Med. 2003 Jan;11(1):49-55 [12469217.001]
  • (PMID = 18664570.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / F32CA113037; United States / NCI NIH HHS / CA / R01-CA87728; United States / NCI NIH HHS / CA / CA113037-03; United States / NCI NIH HHS / CA / F32 CA113037-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Mitogens; 0 / Neoplasm Proteins; 0 / Phosphatidylinositol 4,5-Diphosphate; 0 / Receptors, Growth Factor; 0 / Repressor Proteins; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC2661398
  •  go-up   go-down


35. Sato A, Sueoka-Aragane N, Saitoh J, Komiya K, Hisatomi T, Tomimasu R, Hayashi S, Sueoka E: Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma hnRNP B1 mRNA, a biomarker of lung cancer. J Cancer Res Clin Oncol; 2008 Nov;134(11):1191-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Heterogeneous-Nuclear Ribonucleoprotein Group A-B / blood. Lung Neoplasms / genetics. RNA, Messenger / genetics
  • [MeSH-minor] Base Sequence. DNA Primers. Female. Genetic Markers. Heterogeneous-Nuclear Ribonucleoproteins / genetics. Humans. Male. Molecular Sequence Data. Prognosis. RNA / genetics. RNA, Neoplasm / genetics. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:179-88 [11708476.001]
  • [Cites] Gut. 2002 Apr;50(4):530-4 [11889075.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1404-7 [10197602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3455-9 [2582412.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2511-8 [17955504.001]
  • [Cites] Science. 1994 Jul 29;265(5172):615-21 [8036511.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1896-902 [11280744.001]
  • [Cites] Cancer Res. 1978 Oct;38(10):3546-54 [688240.001]
  • [Cites] Anal Biochem. 2003 Mar 1;314(1):77-86 [12633605.001]
  • [Cites] Biochim Biophys Acta. 2007 Jan;1775(1):181-232 [17137717.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):1961-5 [10473072.001]
  • [Cites] J Clin Microbiol. 2005 Nov;43(11):5435-9 [16272466.001]
  • [Cites] J Cell Biol. 1997 Sep 8;138(5):1077-87 [9281585.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2821-5 [11555599.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Jan 26;280(3):625-30 [11162566.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:172-8 [11708475.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1613-7 [15014011.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6407-12 [2445471.001]
  • [Cites] Lung Cancer. 2005 Apr;48(1):77-83 [15777973.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Aug 11;261(3):646-51 [10441480.001]
  • [Cites] Genomics. 1995 Jan 20;25(2):365-71 [7789969.001]
  • [Cites] Colorectal Dis. 2004 Jul;6(4):236-42 [15206965.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):299-301 [10050857.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4301-10 [8321232.001]
  • [Cites] Mol Cell Biol. 1991 Feb;11(2):864-71 [1990289.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3205-9 [15867214.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):888-95 [15964549.001]
  • [Cites] Nature. 1992 Feb 20;355(6362):730-2 [1371331.001]
  • [Cites] Nucleic Acids Res. 1992 Dec 25;20(24):6461-4 [1282701.001]
  • [Cites] J Cell Biol. 1989 Nov;109(5):1937-46 [2808514.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:192-4 [11708478.001]
  • [Cites] Nucleic Acids Res. 1997 Oct 1;25(19):3950-4 [9380522.001]
  • [Cites] EMBO J. 1994 Nov 15;13(22):5483-95 [7957114.001]
  • (PMID = 18461365.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Genetic Markers; 0 / Heterogeneous-Nuclear Ribonucleoprotein Group A-B; 0 / Heterogeneous-Nuclear Ribonucleoproteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / hnRNP A2; 63231-63-0 / RNA
  •  go-up   go-down


36. Adusumilli PS, Stiles BM, Chan MK, Eisenberg DP, Yu Z, Stanziale SF, Huq R, Wong RJ, Rusch VW, Fong Y: Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. FASEB J; 2006 Apr;20(6):726-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery.
  • Current efforts on expanding minimally invasive techniques into the realm of oncological surgery are hindered by lack of accurate visualization of tumor margins and failure to detect micro metastases in real time.
  • We used a systemic delivery of a herpes viral vector with cancer-selective infection and replication to precisely differentiate between normal and malignant tissue.
  • We tested the potential of NV1066 in delineating tumor tissue in vitro and in vivo in a wide range of cancers and whether NV1066-induced GFP expression can detect small foci of tumors and metastases in in vivo models using an operating endoscope with fluorescent filters.
  • We demonstrate that a single dose of NV1066, administered either locally (intratumoral or intracavitary) or systemically, will detect loco-regional and distant disease throughout the body.
  • Fluorescence-aided minimally invasive endoscopy revealed microscopic tumor deposits unrecognized by conventional laparoscopy/thoracoscopy.
  • Furthermore, NV1066 ability to transit and infect tumor and metastases is proven in syngenic and transplanted tumors in different animal models, both immunocompetent and immunodeficient.
  • These studies form the basis for real-time, intraoperative diagnostic imaging of tumor and metastases by minimally invasive endoscopic technology.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2004 Jun;18(9):1001-3 [15059970.001]
  • [Cites] Cancer Gene Ther. 2006 Jan 1;13(1):53-64 [16037824.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1022-8 [15136930.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6259-65 [15342413.001]
  • [Cites] Curr Gene Ther. 2004 Sep;4(3):337-46 [15384947.001]
  • [Cites] Nature. 1995 Feb 23;373(6516):663-4 [7854443.001]
  • [Cites] Trends Biochem Sci. 1995 Nov;20(11):448-55 [8578587.001]
  • [Cites] FASEB J. 1999 Aug;13(11):1325-34 [10428757.001]
  • [Cites] Surg Clin North Am. 2005 Feb;85(1):1-18, vii [15619524.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12278-82 [11050247.001]
  • [Cites] Hum Gene Ther. 2001 Jan 1;12(1):13-23 [11177538.001]
  • [Cites] Nat Med. 2001 Jul;7(7):859-63 [11433353.001]
  • [Cites] Curr Opin Mol Ther. 1999 Aug;1(4):443-53 [11713758.001]
  • [Cites] Hum Gene Ther. 2002 Jul 1;13(10):1213-23 [12133274.001]
  • [Cites] Nat Med. 2002 Aug;8(8):891-7 [12134144.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):1036-42 [12522442.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):183-9 [12620915.001]
  • [Cites] Surgery. 2003 Aug;134(2):357-64 [12947341.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Sep;Suppl:SS16-21 [14587522.001]
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Surgery. 2004 Mar;135(3):273-81 [14976477.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Semin Laparosc Surg. 2004 Mar;11(1):27-36 [15094976.001]
  • [Cites] Surg Clin North Am. 2005 Feb;85(1):105-18, x [15619532.001]
  • [Cites] Ann Thorac Surg. 2005 Aug;80(2):409-16; discussion 416-7 [16039175.001]
  • [Cites] Nat Rev Cancer. 2005 Oct;5(10):796-806 [16195751.001]
  • [Cites] Hum Gene Ther. 2004 Jun;15(6):609-18 [15212719.001]
  • (PMID = 16467372.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075416; United States / NCI NIH HHS / CA / R01 CA080982; United States / NCI NIH HHS / CA / R01 CA 75416; United States / NCI NIH HHS / CA / R01 CA/DK80982
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indicators and Reagents; 0 / Luminescent Proteins; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS7206; NLM/ PMC1424670
  •  go-up   go-down


37. Kronenwett U, Huwendiek S, Castro J, Ried T, Auer G: Characterisation of breast fine-needle aspiration biopsies by centrosome aberrations and genomic instability. Br J Cancer; 2005 Jan 31;92(2):389-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have suggested that aneuploidy in malignant tumours could be a consequence of centrosome aberrations.
  • Benign lesions did not show any centrosome aberrations.
  • Our results indicate the percentage of cells with centrosome aberrations as being sufficient to divide the investigated tumours into three significantly different groups: benign lesions with no centrosomal aberrations, and two malignant tumour types with mean values of 2.1 and 9.6% of centrosomal defects, respectively.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Centrosome / pathology. DNA, Neoplasm / analysis. Genomic Instability

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol. 1980 Sep;2(3):161-5 [6252802.001]
  • [Cites] Acta Radiol Ther Phys Biol. 1968 Aug;7(4):241-62 [4179434.001]
  • [Cites] Cancer. 1988 Jul 15;62(2):331-41 [3383134.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):521-30 [3390793.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):518-27 [2470665.001]
  • [Cites] Cell. 1991 May 31;65(5):825-36 [1840506.001]
  • [Cites] Radiol Clin North Am. 1992 Jan;30(1):167-85 [1732925.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):80-3 [1538786.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):108-11 [1582502.001]
  • [Cites] Curr Opin Cell Biol. 1993 Feb;5(1):105-15 [8448021.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1348-53 [8276382.001]
  • [Cites] Annu Rev Biochem. 1994;63:639-74 [7979251.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5415-23 [7585611.001]
  • [Cites] Oncology (Williston Park). 1996 Jun;10(6):867-82, 887; discussion 887-90 [8823802.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2765-80 [9205089.001]
  • [Cites] Br J Biomed Sci. 1997 Jun;54(2):140-8 [9231461.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):2950-5 [9501196.001]
  • [Cites] Nature. 1998 Mar 19;392(6673):223-4 [9521314.001]
  • [Cites] Diagn Cytopathol. 1998 Jun;18(6):462-7 [9626523.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3974-85 [9731511.001]
  • [Cites] Cell Motil Cytoskeleton. 1998;41(4):281-8 [9858153.001]
  • [Cites] Nat Cell Biol. 1999 Jun;1(2):88-93 [10559879.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1941-51 [10595924.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Feb;27(2):183-90 [10612807.001]
  • [Cites] Curr Opin Cell Biol. 2000 Feb;12(1):113-8 [10679351.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):82-8 [10687734.001]
  • [Cites] Curr Top Dev Biol. 2000;49:267-89 [11005023.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):279-84 [11301343.001]
  • [Cites] Genes Dev. 2001 May 15;15(10):1167-81 [11358861.001]
  • [Cites] Cell. 2001 May 18;105(4):417-20 [11371338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1978-83 [11830638.001]
  • [Cites] Int J Oncol. 2002 Jun;20(6):1161-5 [12011993.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1398-404 [12649205.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):904-9 [14871819.001]
  • [Cites] Cancer Res. 1984 Jan;44(1):394-6 [6690053.001]
  • (PMID = 15558069.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2361862
  •  go-up   go-down


38. Reiner CL, McCullar JS, Kow RL, Le JH, Goodlett DR, Nathanson NM: RACK1 associates with muscarinic receptors and regulates M(2) receptor trafficking. PLoS One; 2010 Oct 20;5(10):e13517
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The M(2) muscarinic acetylcholine receptor undergoes internalization via a poorly-defined clathrin-independent mechanism.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2005 Feb;6(2):112-26 [15687999.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Biochem J. 2006 Aug 15;398(1):23-36 [16689683.001]
  • [Cites] Traffic. 2008 Mar;9(3):394-407 [18088317.001]
  • [Cites] Life Sci. 2008 Mar 26;82(13-14):718-27 [18295803.001]
  • [Cites] J Biol Chem. 2000 Jul 28;275(30):23295-302 [10930431.001]
  • [Cites] J Cell Sci. 2001 Feb;114(Pt 4):739-46 [11171379.001]
  • [Cites] Mol Pharmacol. 2001 May;59(5):1256-68 [11306711.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1532-9 [11313899.001]
  • [Cites] Biochem Soc Trans. 2001 Aug;29(Pt 4):505-8 [11498018.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Jan;34(1):93-102 [11733189.001]
  • [Cites] J Biol Chem. 2002 Jan 4;277(1):702-10 [11696538.001]
  • [Cites] Prog Neurobiol. 2002 Feb;66(2):61-79 [11900882.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5710-5 [11943848.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):512-5 [11981568.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33439-46 [12093817.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49888-95 [12359736.001]
  • [Cites] J Neurosci. 2003 May 1;23(9):3623-32 [12736333.001]
  • [Cites] Rapid Commun Mass Spectrom. 2003;17(18):2093-8 [12955739.001]
  • [Cites] J Cell Sci. 2003 Dec 1;116(Pt 23):4707-14 [14600257.001]
  • [Cites] Life Sci. 2003 Dec 5;74(2-3):217-24 [14607249.001]
  • [Cites] Traffic. 2003 Nov;4(11):724-38 [14617356.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23630-6 [15037627.001]
  • [Cites] Mol Cell Biol. 2004 Aug;24(15):6788-98 [15254245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):839-43 [8302854.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15640-5 [8195213.001]
  • [Cites] J Biol Chem. 1997 May 30;272(22):14152-8 [9162044.001]
  • [Cites] J Biol Chem. 1997 Jul 25;272(30):18882-90 [9228066.001]
  • [Cites] J Biol Chem. 1998 May 15;273(20):12155-60 [9575162.001]
  • [Cites] Prog Neurobiol. 2006 Feb;78(2):117-34 [16457939.001]
  • (PMID = 20976005.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / R01-ES015594; United States / NHLBI NIH HHS / HL / P01-HL44948; United States / NHLBI NIH HHS / HV / N01-HV-8179; United States / NHLBI NIH HHS / HL / P01 HL044948; United States / NIEHS NIH HHS / ES / R01 ES015594; United States / NIGMS NIH HHS / GM / T32 GM 07727
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Affinity Labels; 0 / GNB2L1 protein, human; 0 / Neoplasm Proteins; 0 / Receptor, Muscarinic M2; 0 / Receptors, Cell Surface; EC 3.6.1.- / GTP-Binding Proteins
  • [Other-IDs] NLM/ PMC2958127
  •  go-up   go-down


39. Lowe DB, Shearer MH, Aldrich JF, Winn RE, Jumper CA, Kennedy RC: Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen. J Virol; 2010 Oct;84(19):10121-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of the innate immune response and tumor immunity associated with simian virus 40 large tumor antigen.
  • We examined properties of the innate immune response against the tumor-specific antigen simian virus 40 (SV40) large tumor antigen (Tag) following experimental pulmonary metastasis in naive mice.
  • Approximately 14 days after mKSA tumor cell challenge, expression of inflammatory mediators such as tumor necrosis factor alpha (TNF-alpha), interleukin-2 (IL-2), and RANTES was upregulated in splenocytes harvested from mice, as assessed by flow cytometry and antibody array assays.
  • This response was hypothesized to activate and induce tumor-directed NK cell lysis since IL-2-stimulated NK cells mediated tumor cell destruction in vitro.
  • The necessary function of NK cells was further validated in vivo through selected antibody depletion of NK cells, which resulted in an overwhelming lung tumor burden relative to that in animals receiving a control rabbit IgG depletion regimen.
  • In a separate study, mice receiving treatments of poly(I:C) and recombinant SV40 Tag protein immunization mounted effective tumor immunity in an established experimental pulmonary metastasis setting.
  • These data have direct implications for immunotherapeutic strategies incorporating methods to elicit inflammatory reactions, particularly NK cell-driven lysis, against malignant cell types that express a tumor-specific antigen such as SV40 Tag.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Immunol Immunother. 2002 Feb;50(12):682-90 [11862420.001]
  • [Cites] J Immunol. 2008 Jun 15;180(12):7785-91 [18523242.001]
  • [Cites] Int J Cancer. 1969 Jul 15;4(4):384-92 [4310402.001]
  • [Cites] J Immunol. 1987 Feb 15;138(4):1215-20 [3027174.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1781-90 [8183577.001]
  • [Cites] J Immunol. 1994 Sep 1;153(5):2064-71 [8051411.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1126-30 [8640771.001]
  • [Cites] Anal Biochem. 1998 Feb 15;256(2):217-9 [9473280.001]
  • [Cites] J Virol Methods. 1997 Dec;69(1-2):93-102 [9504755.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4505-9 [9788590.001]
  • [Cites] Cancer Immunol Immunother. 1999 Feb;47(6):343-51 [10203065.001]
  • [Cites] Mol Immunol. 2005 Feb;42(4):535-9 [15607810.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):767-76 [15634897.001]
  • [Cites] Virology. 2005 Feb 5;332(1):28-37 [15661138.001]
  • [Cites] Immunity. 2005 Jul;23(1):41-51 [16039578.001]
  • [Cites] Immunity. 2006 Jan;24(1):19-28 [16413920.001]
  • [Cites] J Virol. 2007 Feb;81(3):1313-8 [17108042.001]
  • [Cites] Cancer Immunol Immunother. 2007 Oct;56(10):1625-36 [17431618.001]
  • [Cites] Cell Mol Life Sci. 2007 Sep;64(18):2391-403 [17565444.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):208-17 [18176602.001]
  • [Cites] Oncogene. 2008 Jan 7;27(2):218-24 [18176603.001]
  • [Cites] Nat Immunol. 2008 May;9(5):486-94 [18425105.001]
  • [Cites] J Med Virol. 2008 Aug;80(8):1497-504 [18551603.001]
  • [Cites] N Engl J Med. 2008 Jun 19;358(25):2704-15 [18565863.001]
  • [Cites] Nat Rev Cancer. 2008 Nov;8(11):887-99 [18846100.001]
  • [Cites] Eur J Immunol. 2008 Nov;38(11):2938-42 [18979519.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):57-63 [19052556.001]
  • [Cites] Nat Rev Immunol. 2009 Aug;9(8):535-42 [19556980.001]
  • [Cites] Nat Rev Immunol. 2009 Aug;9(8):568-80 [19629084.001]
  • [Cites] Eur J Immunol. 2009 Aug;39(8):2059-64 [19637199.001]
  • [Cites] J Exp Med. 2009 Dec 21;206(13):2967-76 [19995959.001]
  • [Cites] J Virol. 2010 Jan;84(2):883-93 [19889780.001]
  • [Cites] Cell. 2010 Mar 19;140(6):883-99 [20303878.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1040-5 [12615720.001]
  • (PMID = 20668083.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P40 RR012317; United States / NCRR NIH HHS / RR / RR-12317
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Polyomavirus Transforming; 0 / Interleukin-2; 0 / Toll-Like Receptors; 24939-03-5 / Poly I-C
  • [Other-IDs] NLM/ PMC2937757
  •  go-up   go-down


40. Riemer AB, Jensen-Jarolim E: Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett; 2007 Oct 31;113(1):1-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is important as antibodies directed against tumor-associated antigens may harbor diverse biological effects depending on their epitope specificity.
  • Thus they may inhibit or promote tumor growth.
  • [MeSH-major] Antibodies, Neoplasm / biosynthesis. Antigens, Neoplasm / immunology. Cancer Vaccines / immunology. Epitopes / immunology. Molecular Mimicry / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1994 Jan 15;54(2):415-21 [8275478.001]
  • [Cites] J Immunol. 2001 Apr 15;166(8):5271-8 [11290813.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3384-8 [10910043.001]
  • [Cites] Ann Immunol (Paris). 1974 Jan;125C(1-2):373-89 [4142565.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):394-401 [15210798.001]
  • [Cites] Adv Immunol. 2000;74:181-273 [10605607.001]
  • [Cites] Cell Res. 1999 Dec;9(4):271-80 [10628836.001]
  • [Cites] FASEB J. 2000 Nov;14(14):2177-84 [11053238.001]
  • [Cites] J Immunol. 1995 Apr 1;154(7):3162-72 [7534789.001]
  • [Cites] Gene. 1993 Jun 15;128(1):51-7 [7685301.001]
  • [Cites] Nat Med. 1998 May;4(5 Suppl):525-31 [9585204.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):976-82 [15634921.001]
  • [Cites] Eur J Immunol. 2006 May;36(5):1267-74 [16568495.001]
  • [Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]
  • [Cites] Cancer Immunol Immunother. 1993 Sep;37(4):255-63 [8102322.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10567-75 [17079481.001]
  • [Cites] Gene. 1993 Jun 15;128(1):21-7 [7685299.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):660-5 [10404158.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jul;54(7):677-84 [15565329.001]
  • [Cites] Gene. 1988 Dec 20;73(2):305-18 [3149606.001]
  • [Cites] J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70 [16288119.001]
  • [Cites] Vaccine. 2007 Apr 20;25(16):3022-31 [17303294.001]
  • [Cites] Hybridoma. 1999 Feb;18(1):103-12 [10211797.001]
  • [Cites] Anal Biochem. 1996 Jun 15;238(1):1-13 [8660577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3353-7 [7724565.001]
  • [Cites] Mol Biol Med. 1983 Dec;1(5):511-29 [6094961.001]
  • [Cites] Science. 1990 Jul 27;249(4967):404-6 [2143033.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):428-34 [12402315.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Apr;87(7):2569-73 [1969636.001]
  • [Cites] N Engl J Med. 1982 Mar 4;306(9):517-22 [6173751.001]
  • [Cites] Hybridoma. 1995 Apr;14(2):175-81 [7590776.001]
  • [Cites] Ann N Y Acad Sci. 1999;886:276-9 [10667238.001]
  • [Cites] Mol Immunol. 2005 May;42(9):1121-4 [15829301.001]
  • [Cites] J Clin Invest. 1990 Dec;86(6):2136-44 [2254463.001]
  • [Cites] Cancer Res. 1990 Mar 1;50(5):1550-8 [1689212.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3410-8 [15833876.001]
  • [Cites] Clin Mol Pathol. 1995 Jun;48(3):M136-41 [16695994.001]
  • [Cites] Vaccine. 1997 Aug;15(11):1276-85 [9286056.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3594-602 [17530013.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] J Immunol. 2006 May 15;176(10):6046-54 [16670313.001]
  • [Cites] Peptides. 1999;20(9):1021-6 [10499418.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6378-82 [2201029.001]
  • [Cites] Curr Opin Mol Ther. 2000 Feb;2(1):74-9 [11249654.001]
  • [Cites] FASEB J. 1998 Dec;12(15):1635-42 [9837853.001]
  • [Cites] Science. 1985 Jun 14;228(4705):1315-7 [4001944.001]
  • [Cites] Mol Immunol. 2005 Feb;42(3):319-25 [15589320.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8691-5 [1717984.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3629-35 [10999755.001]
  • (PMID = 17825923.001).
  • [ISSN] 0165-2478
  • [Journal-full-title] Immunology letters
  • [ISO-abbreviation] Immunol. Lett.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18238
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Epitopes
  • [Number-of-references] 49
  • [Other-IDs] NLM/ PMC2999752; NLM/ UKMS33000
  •  go-up   go-down


41. Strander B, Ryd W, Wallin KL, Wärleby B, Zheng B, Milsom I, Gharizadeh B, Pourmand N, Andersson-Ellström A: Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer; 2007 Aug;43(12):1849-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High risk-HPV-DNA were analysed with PCR from two archival smears per woman.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1997 Oct;28(10):1196-203 [9343327.001]
  • [Cites] Gynecol Oncol. 1999 Feb;72(2):199-201 [10021301.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S16-24 [15753008.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):198-205 [15858143.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1794-9 [15827556.001]
  • [Cites] Mol Cell Probes. 2006 Jun-Aug;20(3-4):230-8 [16516439.001]
  • [Cites] Int J Cancer. 2006 Dec 1;119(11):2677-84 [16991121.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):4157-62 [17005760.001]
  • [Cites] BJOG. 2002 May;109(5):579-81 [12066952.001]
  • [Cites] J Med Virol. 2002 Apr;66(4):535-41 [11857534.001]
  • [Cites] Br J Cancer. 2001 Mar 23;84(6):796-801 [11259094.001]
  • [Cites] Am J Obstet Gynecol. 2000 Nov;183(5):1238-42 [11084572.001]
  • [Cites] Int J Cancer. 2000 Dec 1;88(5):698-701 [11072236.001]
  • [Cites] Obstet Gynecol. 2000 Jun;95(6 Pt 1):828-31 [10831975.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1421-6 [10780521.001]
  • [Cites] Acta Obstet Gynecol Scand. 2000 Mar;79(3):221-6 [10716304.001]
  • [Cites] N Engl J Med. 1999 Nov 25;341(22):1633-8 [10572150.001]
  • [Cites] Am J Obstet Gynecol. 1996 Mar;174(3):937-42 [8633673.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):108-13 [9234930.001]
  • [Cites] Lancet. 1997 Apr 5;349(9057):978-80 [9100623.001]
  • [Cites] Anal Quant Cytol Histol. 1995 Aug;17(4):221-9 [8526946.001]
  • [Cites] Lancet. 1994 Jan 1;343(8888):32-4 [7905048.001]
  • [Cites] Obstet Gynecol. 1992 Jan;79(1):105-10 [1727567.001]
  • [Cites] Radiother Oncol. 1989 Oct;16(2):115-20 [2595011.001]
  • [Cites] Obstet Gynecol Surv. 2004 Jul;59(7):543-53 [15199273.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):295-304 [12861176.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):67-73 [14529664.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):205-11 [15023438.001]
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 1):965-71 [12423862.001]
  • [Cites] Int J Cancer. 2002 Nov 10;102(2):148-51 [12385010.001]
  • (PMID = 17614272.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] ENG
  • [Grant] United States / NHGRI NIH HHS / HG / HG000205-190004; United States / NHGRI NIH HHS / HG / P01 HG000205; United States / NHGRI NIH HHS / HG / P01 HG000205-190004
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS151296; NLM/ PMC2933034
  •  go-up   go-down


42. Schumacher JA, Crockett DK, Elenitoba-Johnson KS, Lim MS: Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells. J Mol Diagn; 2007 Apr;9(2):169-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Mass Spectrometry / methods. Neoplasm Proteins / analysis. Neoplasms / metabolism. Phosphoproteins / analysis. Phosphotyrosine / analysis
  • [MeSH-minor] Amino Acid Sequence. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Chromatography, Affinity. Chromatography, Liquid. Humans. Immunoprecipitation. Molecular Sequence Data. Vanadates / pharmacology

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1989 Mar 24;243(4898):1564-70 [2538922.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(7):1127-34 [16521170.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1296-300 [7527617.001]
  • [Cites] Trends Biochem Sci. 1994 Nov;19(11):459-63 [7855887.001]
  • [Cites] Nature. 1995 Jul 20;376(6537):267-71 [7617039.001]
  • [Cites] Blood. 1995 Nov 1;86(9):3517-21 [7579458.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Lung Cancer. 1997 May;17(1):69-84 [9194028.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1057-62 [9500471.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2194-9 [11280786.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Proteomics. 2001 Feb;1(2):207-22 [11680868.001]
  • [Cites] J Immunol. 2002 Jan 1;168(1):466-74 [11751994.001]
  • [Cites] Keio J Med. 2002 Jun;51(2):61-71 [12125907.001]
  • [Cites] Mol Cell Proteomics. 2002 Jul;1(7):517-27 [12239280.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30028-36 [12748172.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7750-61 [14586401.001]
  • [Cites] AMIA Annu Symp Proc. 2003;:839 [14728344.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] J Biol Chem. 2004 Apr 16;279(16):15805-13 [14739304.001]
  • [Cites] Proteomics. 2004 Jul;4(7):1985-8 [15221759.001]
  • [Cites] J Biol Chem. 1984 Aug 10;259(15):9580-6 [6204986.001]
  • [Cites] Nature. 1988 Sep 1;335(6185):88-9 [2457811.001]
  • [Cites] Biotechnol Prog. 1998 Nov-Dec;14(6):943-50 [9841659.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] N Engl J Med. 2005 Jul 14;353(2):172-87 [16014887.001]
  • [Cites] J Biomol Tech. 2005 Jun;16(2):91-103 [16030316.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):667-75 [16118637.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7628-34 [16140928.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • (PMID = 17384208.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; 0 / Phosphoproteins; 21820-51-9 / Phosphotyrosine; 3WHH0066W5 / Vanadates
  • [Other-IDs] NLM/ PMC1867451
  •  go-up   go-down


43. Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, Sanchez BA, Valles I, Pajares MJ, Pio R, Rodriguez MJ, Montuenga LM, Calvo A: Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol; 2008;9:103
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene expression was measured by quantitative real time RT-PCR and expression stability was analyzed with the softwares GeNorm and NormFinder, mean of |Delta Ct| (= |Ct Normal-Ct tumor|) +/- SEM, and correlation coefficients among genes.
  • Further analysis showed that IPO8 had a very low mean of |Delta Ct| (0.70 +/- 0.09), with no statistically significant differences between normal and malignant samples and with excellent expression stability.
  • [MeSH-major] Genes, Neoplasm. Lung / metabolism. Lung / pathology. beta Karyopherins / genetics
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) / metabolism. Humans. Hypoxanthine Phosphoribosyltransferase / metabolism. Reference Standards. Reverse Transcriptase Polymerase Chain Reaction. Software

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7431-8 [17671213.001]
  • [Cites] Clin Chem. 2007 Aug;53(8):1433-9 [17599955.001]
  • [Cites] Physiol Genomics. 2007 Aug 20;30(3):363-70 [17456737.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3436-44 [17948124.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12776-81 [11070089.001]
  • [Cites] Am J Respir Crit Care Med. 2000 Nov;162(5):1957-63 [11069840.001]
  • [Cites] Anal Biochem. 2001 Aug 1;295(1):17-21 [11476540.001]
  • [Cites] J Cell Sci. 2001 Oct;114(Pt 19):3479-85 [11682607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Leukemia. 2003 Apr;17(4):789-95 [12682639.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3902-8 [14507943.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1878-85 [15143080.001]
  • [Cites] Lung Cancer. 2004 Mar;43(3):285-95 [15165086.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5245-50 [15289330.001]
  • [Cites] Biochim Biophys Acta. 1999 Jul 13;1432(2):159-84 [10407139.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):409-21 [15653641.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Eur Respir J. 2005 Dec;26(6):1002-8 [16319328.001]
  • [Cites] J Mol Med (Berl). 2005 Dec;83(12):1014-24 [16211407.001]
  • [Cites] J Urol. 2006 May;175(5):1915-20 [16600798.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G1067-74 [16399877.001]
  • [Cites] N Engl J Med. 2007 Jan 4;356(1):11-20 [17202451.001]
  • [Cites] Nat Rev Cancer. 2007 Jul;7(7):545-53 [17585334.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1130-4 [17554337.001]
  • [Cites] BMC Mol Biol. 2007;8:47 [17559644.001]
  • [Cites] BMC Genomics. 2007;8:243 [17640361.001]
  • (PMID = 19014639.001).
  • [ISSN] 1471-2199
  • [Journal-full-title] BMC molecular biology
  • [ISO-abbreviation] BMC Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / IPO8 protein, human; 0 / beta Karyopherins; EC 1.2.1.12 / Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating); EC 2.4.2.8 / Hypoxanthine Phosphoribosyltransferase
  • [Other-IDs] NLM/ PMC2612021
  •  go-up   go-down


44. Dudani AK, Mehic J, Martyres A: Plasminogen and angiostatin interact with heat shock proteins. Mol Cell Biochem; 2007 Jun;300(1-2):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Actins / pharmacology. Binding, Competitive / drug effects. Chaperonin 60 / metabolism. HSP27 Heat-Shock Proteins. HSP70 Heat-Shock Proteins / metabolism. Humans. Ligands. Lysine / pharmacology. Neoplasm Proteins / metabolism. Protein Binding / drug effects

  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2227-31 [2006162.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Sep;75(9):4484-8 [309133.001]
  • [Cites] Proteomics. 2004 Oct;4(10):2991-3006 [15378750.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):33564-70 [12087108.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):3815-9 [8483899.001]
  • [Cites] Blood. 1991 Dec 15;78(12):3114-24 [1742478.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1217-21 [7679494.001]
  • [Cites] FASEB J. 1998 Nov;12(14):1481-90 [9806757.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:d1-8 [12456318.001]
  • [Cites] Thromb Res. 1993 Jan 15;69(2):185-96 [8383363.001]
  • [Cites] Circ Res. 2004 Apr 16;94(7):902-9 [15001530.001]
  • [Cites] Cell. 1994 Oct 21;79(2):315-28 [7525077.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1991;60(5):279-86 [1685034.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1247-54 [11257124.001]
  • [Cites] Br J Haematol. 1996 Oct;95(1):168-78 [8857956.001]
  • [Cites] J Cereb Blood Flow Metab. 1989 Oct;9(5):675-80 [2777936.001]
  • [Cites] J Biol Chem. 1996 Oct 11;271(41):25684-91 [8810346.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):21191-7 [8063740.001]
  • [Cites] Circ Res. 1994 Dec;75(6):1078-85 [7525102.001]
  • [Cites] Clin Microbiol Rev. 1999 Jan;12(1):19-39 [9880473.001]
  • [Cites] Biochem Cell Biol. 1994 Mar-Apr;72(3-4):126-31 [7818846.001]
  • [Cites] Mol Cell Biochem. 1991 Dec 11;108(2):133-9 [1664040.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):909-16 [11556845.001]
  • [Cites] Biochemistry. 1991 Feb 12;30(6):1682-91 [1847072.001]
  • [Cites] J Biol Chem. 2003 Feb 28;278(9):7607-16 [12493773.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):448-62 [12453439.001]
  • [Cites] J Surg Oncol. 1999 Jun;71(2):130-5 [10389872.001]
  • [Cites] Cell Stress Chaperones. 2002 Apr;7(2):167-76 [12380684.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem Cell Biol. 1991 Jul;69(7):442-8 [1793556.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1547-59 [12377729.001]
  • [Cites] Hum Pathol. 1987 Mar;18(3):234-9 [3546072.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811-6 [10077593.001]
  • [Cites] Thromb Haemost. 1996 Feb;75(2):352-8 [8815589.001]
  • [Cites] Expert Rev Mol Med. 2001 Sep 21;3(23):1-21 [14585147.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 19;95(22):1660-73 [14625257.001]
  • [Cites] EXS. 1997;79:273-94 [9002223.001]
  • [Cites] Biochem Cell Biol. 2005 Feb;83(1):28-35 [15746964.001]
  • (PMID = 17206383.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Actins; 0 / Chaperonin 60; 0 / HSP27 Heat-Shock Proteins; 0 / HSP70 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Ligands; 0 / Neoplasm Proteins; 86090-08-6 / Angiostatins; 9001-91-6 / Plasminogen; K3Z4F929H6 / Lysine
  •  go-up   go-down


45. Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J: A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors. BMC Med Genomics; 2010;3:26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
  • METHODS: We used the coherent expression of RAS pathway-related genes across multiple datasets to derive a RAS pathway gene expression signature and generate RAS pathway activation scores in pre-clinical cancer models and human tumors.
  • RESULTS: The RAS signature score is predictive of KRAS mutation status in lung tumors and cell lines with high (> 90%) sensitivity but relatively low (50%) specificity due to samples that have apparent RAS pathway activation in the absence of a KRAS mutation.
  • In human tumors, the RAS pathway signature is elevated in ER negative breast tumors and lung adenocarcinomas, and predicts resistance to cetuximab in metastatic colorectal cancer.
  • CONCLUSIONS: These data demonstrate that the RAS pathway signature is superior to KRAS mutation status for the prediction of dependence on RAS signaling, can predict response to PI3K and RAS pathway inhibitors, and is likely to have the most clinical utility in lung and breast tumors.
  • [MeSH-major] Gene Expression Profiling. Neoplasms / metabolism. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Signal Transduction / drug effects. ras Proteins / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antineoplastic Agents / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Cell Line, Tumor. Cetuximab. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / genetics. Databases, Genetic. Drug Resistance, Neoplasm. Enzyme Inhibitors / pharmacology. Female. Gene Expression Regulation, Neoplastic. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / genetics. Mitogen-Activated Protein Kinase Kinases / antagonists & inhibitors. Mitogen-Activated Protein Kinase Kinases / metabolism. Mutation. Proto-Oncogene Proteins / antagonists & inhibitors. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. Proto-Oncogene Proteins c-akt / antagonists & inhibitors. Proto-Oncogene Proteins c-akt / metabolism. RNA Interference. RNA, Small Interfering / metabolism

  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):342-7 [11283592.001]
  • [Cites] J Clin Oncol. 2010 Feb 20;28(6):1075-83 [20085938.001]
  • [Cites] Nat Rev Cancer. 2003 Jan;3(1):11-22 [12509763.001]
  • [Cites] Nat Med. 1999 Jul;5(7):810-6 [10395327.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Br J Cancer. 2005 Jan 17;92(1):131-9 [15597105.001]
  • [Cites] BMC Bioinformatics. 2005;6:265 [16271137.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s [16609061.001]
  • [Cites] Anal Biochem. 2006 Jun 1;353(1):43-56 [16624241.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Nat Genet. 2007 Mar;39(3):347-51 [17293865.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3320-8 [17409441.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 1:S5 [17430572.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3230-7 [17664471.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1626-34 [18316791.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jun;47(6):530-42 [18335499.001]
  • [Cites] N Engl J Med. 2008 Oct 23;359(17):1757-65 [18946061.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5705-12 [19001320.001]
  • [Cites] Lancet Oncol. 2008 Oct;9(10):962-72 [18804418.001]
  • [Cites] Genome Biol. 2008;9(12):R180 [19094238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24 [19251651.001]
  • [Cites] Mol Cell. 2009 Apr 10;34(1):104-14 [19362539.001]
  • [Cites] Clin Pharmacol Ther. 2009 Jul;86(1):92-6 [19387436.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Jul;6(7):371 [19561629.001]
  • [Cites] Adv Cancer Res. 2009;102:1-17 [19595305.001]
  • [Cites] Clin Cancer Res. 2009 Aug 15;15(16):5267-73 [19671843.001]
  • [Cites] Oncogene. 2001 Apr 12;20(16):1981-9 [11360182.001]
  • (PMID = 20591134.001).
  • [ISSN] 1755-8794
  • [Journal-full-title] BMC medical genomics
  • [ISO-abbreviation] BMC Med Genomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.6.5.2 / ras Proteins; PQX0D8J21J / Cetuximab
  • [Other-IDs] NLM/ PMC2911390
  •  go-up   go-down


46. Shen F, Bailey BJ, Chu S, Bence AK, Xue X, Erickson P, Safa AR, Beck WT, Erickson LC: Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells. J Pharmacol Exp Ther; 2009 Aug;330(2):423-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In living animals, the accumulation of mitoxantrone in MDA-MB-435mdr xenograft tumors was 61% of that in the wild-type tumors.
  • Administration of PSC833 to animals before mitoxantrone treatment increased the accumulation of mitoxantrone in the MDR tumors to 94% of that in the wild-type tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Ther. 2003 Jul;2(7):661-70 [12883039.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):581-9 [12879476.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Cancer Res. 1980 May;40(5):1516-8 [7370989.001]
  • [Cites] Biochim Biophys Acta. 1988 Jan 25;949(1):132-7 [3334848.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4226-33 [1678313.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):4000-8 [1617677.001]
  • [Cites] Annu Rev Biochem. 1993;62:385-427 [8102521.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;35(5):403-10 [7850922.001]
  • [Cites] Acta Oncol. 1995;34(2):235-41 [7718262.001]
  • [Cites] Biophys J. 1997 Dec;73(6):3328-36 [9414243.001]
  • [Cites] Eur J Cancer Care (Engl). 1997 Dec;6(4 Suppl):1-3 [9460335.001]
  • [Cites] Blood. 1999 Feb 1;93(3):787-95 [9920827.001]
  • [Cites] Toxicol Appl Pharmacol. 2005 May 1;204(3):216-37 [15845415.001]
  • [Cites] Eur J Pharm Sci. 2006 Apr;27(5):392-400 [16352426.001]
  • [Cites] Cancer Invest. 2006 Nov;24(7):677-81 [17118777.001]
  • [Cites] Drug Metab Dispos. 2007 May;35(5):822-8 [17296624.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jan;324(1):95-102 [17947497.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):205-23 [18248313.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 6:149-53 [10676567.001]
  • [Cites] Leuk Res. 2000 Mar;24(3):249-54 [10739007.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] J Cell Sci. 2000 Jun;113 ( Pt 11):2011-21 [10806112.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1577-90 [11745237.001]
  • [Cites] Drugs. 2001;61(15):2177-92 [11772129.001]
  • [Cites] Prog Drug Res. 2002;58:99-131 [12079203.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):97-104 [12491510.001]
  • [Cites] J Exp Ther Oncol. 2003 Mar-Apr;3(2):72-82 [12822513.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7468-85 [14576852.001]
  • (PMID = 19423841.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA9683901
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / P-Glycoprotein; 121584-18-7 / valspodar; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ PMC2713081
  •  go-up   go-down


47. Arellano-Garcia ME, Hu S, Wang J, Henson B, Zhou H, Chia D, Wong DT: Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva. Oral Dis; 2008 Nov;14(8):705-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplexed immunobead-based assay for detection of oral cancer protein biomarkers in saliva.
  • OBJECTIVE: For clinical applications of biomarkers, there is a need for multiplex assays using high throughput platforms.
  • The objective of this study was to determine the efficacy of Luminex Multianalyte Profiling (xMAP) technology for measurement of salivary proteins and to evaluate whether multiplex assays are as effective as single-plex assays and enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The average levels of interleukin-8 (IL-8) from the single-plex assay were 3313.2 +/- 3759.8 pg ml(-1) [oral squamous cell carcinoma (OSCC), n = 20] and 1061.7 +/- 1978.8 pg ml(-1) (control, n = 20).
  • The IL-1beta average levels from the single-plex assay were 945.2 +/- 1134.8 pg ml(-1) (OSCC, n = 20) and 314.2 +/- 444.8 pg ml(-1) (control, n = 20).
  • The average levels of IL-8 from the multiplex assay were 2834.9 +/- 3385.6 pg ml(-1) (OSCC, n = 20) and 947.3 +/- 2036.8 pg ml(-1) (control, n = 20).
  • The IL-1beta average levels from the multiplex assay were 1013.5 +/- 1221.1 pg ml(-1) (OSCC, n = 20) and 376.3 +/- 576.3 pg ml(-1) (control, n = 20).
  • The correlation coefficient between Luminex and ELISA assay for IL-8 (n = 19) and IL-1beta (n = 19) was 0.91 and 0.84, respectively.
  • CONCLUSION: Luminex xMAP single-plex and multiplex assays are as effective as ELISA assays for quantification of proteins in saliva.
  • Both IL-8 and IL-1beta were expressed at significantly higher levels in OSCC subjects than in the matched healthy control subjects.

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2000;18(2):101-9 [10705871.001]
  • [Cites] Arthritis Rheum. 2007 Nov;56(11):3588-600 [17968930.001]
  • [Cites] Cytometry. 2001 Sep 1;45(1):27-36 [11598944.001]
  • [Cites] J Immunol Methods. 2002 Feb 1;260(1-2):207-18 [11792390.001]
  • [Cites] Int J Oral Maxillofac Surg. 2002 Apr;31(2):145-53 [12102411.001]
  • [Cites] Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9 [12522051.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Aug;130(8):929-35 [15313862.001]
  • [Cites] Ann Clin Biochem. 1992 Sep;29 ( Pt 5):519-22 [1280027.001]
  • [Cites] Clin Chem. 1997 Sep;43(9):1749-56 [9299971.001]
  • [Cites] Clin Chem. 1998 Sep;44(9):2057-60 [9733011.001]
  • [Cites] Cytometry. 1998 Oct 1;33(2):234-43 [9773885.001]
  • [Cites] J Immunol Methods. 1999 Jul 30;227(1-2):41-52 [10485253.001]
  • [Cites] J Pharm Biomed Anal. 2005 Jan 4;36(5):1037-44 [15620530.001]
  • [Cites] Cancer Detect Prev. 2005;29(1):42-5 [15734216.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Proteomics. 2005 Apr;5(6):1714-28 [15800970.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1102-9 [15976097.001]
  • [Cites] J Reprod Immunol. 2005 Aug;66(2):175-91 [16029895.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):228-33 [16552233.001]
  • [Cites] Methods. 2006 Apr;38(4):294-303 [16481197.001]
  • [Cites] Methods. 2006 Apr;38(4):317-23 [16481199.001]
  • [Cites] Oral Oncol. 2006 Apr;42(4):370-3 [16324876.001]
  • [Cites] Electrophoresis. 2006 Apr;27(7):1417-23 [16568407.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):310-20 [16582876.001]
  • [Cites] Cytometry A. 2006 May;69(5):318-25 [16604537.001]
  • [Cites] Rheumatology (Oxford). 2006 Sep;45(9):1077-86 [16522680.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):102-7 [17220337.001]
  • [Cites] Head Neck. 2007 May;29(5):472-8 [17111427.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3182-90 [17545521.001]
  • [Cites] Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):40-9 [17512608.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):243-55 [10986418.001]
  • (PMID = 19193200.001).
  • [ISSN] 1601-0825
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / U01 DE016275; United States / NIDCR NIH HHS / DE / R03 DE017144-02; United States / NIDCR NIH HHS / DE / R03-DE017144; United States / NIDCR NIH HHS / DE / U01 DE016275-03; United States / NIDCR NIH HHS / DE / DE016275-03; United States / NIDCR NIH HHS / DE / R03 DE017144
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogenic Compounds; 0 / Interleukin-1beta; 0 / Interleukin-8; 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  • [Other-IDs] NLM/ NIHMS109836; NLM/ PMC2675698
  •  go-up   go-down


48. Chou CJ, Herman D, Gottesfeld JM: Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem; 2008 Dec 19;283(51):35402-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Members of this class of compounds have shown efficacy in cell-based and mouse models for the neurodegenerative diseases Friedreich ataxia and Huntington disease.
  • Inhibitor 106 also has preference toward HDAC3 with K(i) of approximately 14 nm, 15 times lower than the K(i) for HDAC1.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Friedreich's Ataxia.
  • MedlinePlus Health Information. consumer health - Huntington's Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15564-9 [18829438.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):693-8 [11257101.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jun;2(6):422-32 [11389466.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Chem Biol. 2002 Jan;9(1):3-16 [11841934.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25748-55 [11948178.001]
  • [Cites] Chem Biol. 2003 Jan;10(1):61-8 [12573699.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):737-49 [12429021.001]
  • [Cites] J Am Chem Soc. 2003 May 14;125(19):5586-7 [12733869.001]
  • [Cites] Anal Biochem. 2003 Oct 15;321(2):202-8 [14511685.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Nov;307(2):720-8 [12975486.001]
  • [Cites] Annu Rev Biochem. 2004;73:417-35 [15189148.001]
  • [Cites] Eur J Biochem. 2004 Jul;271(14):2855-62 [15233782.001]
  • [Cites] Biochem J. 1975 Aug;149(2):305-12 [1180900.001]
  • [Cites] Biochemistry. 1982 Jul 6;21(14):3364-70 [7115676.001]
  • [Cites] Adv Enzymol Relat Areas Mol Biol. 1988;61:201-301 [3281418.001]
  • [Cites] Anal Biochem. 1994 Aug 15;221(1):53-6 [7985803.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7 [9501205.001]
  • [Cites] Curr Opin Chem Biol. 1997 Oct;1(3):300-8 [9667866.001]
  • [Cites] Curr Opin Genet Dev. 1999 Feb;9(1):40-8 [10072350.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7 [10200307.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3923-31 [15897550.001]
  • [Cites] Nat Chem Biol. 2006 Oct;2(10):551-8 [16921367.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1138-48 [17455259.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Aug 15;17(16):4619-24 [17555962.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5439-49 [17694085.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2667-73 [17606765.001]
  • [Cites] J Biol Chem. 2007 Oct 5;282(40):29101-13 [17684009.001]
  • [Cites] Pharmacol Ther. 2007 Nov;116(2):236-48 [17826840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 30;104(44):17335-40 [17956988.001]
  • [Cites] Curr Pharm Des. 2008;14(6):529-44 [18336298.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Mar 15;18(6):1814-9 [18308563.001]
  • [Cites] PLoS One. 2008;3(4):e1958 [18463734.001]
  • [Cites] Bioorg Med Chem Lett. 2008 Jun 1;18(11):3456-61 [18440229.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3441-9 [18519775.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5165-70 [11016644.001]
  • (PMID = 18953021.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R21-NS055781
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 0 / Isoenzymes; 0 / Neoplasm Proteins; 0 / Pimelic Acids; 0 / pimelic diphenylamide 106; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC2602898
  •  go-up   go-down


49. Kudo T, Nakagawa H, Takahashi M, Hamaguchi J, Kamiyama N, Yokoo H, Nakanishi K, Nakagawa T, Kamiyama T, Deguchi K, Nishimura S, Todo S: N-glycan alterations are associated with drug resistance in human hepatocellular carcinoma. Mol Cancer; 2007;6:32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Correlations of disease phenotypes with glycosylation changes have been analysed intensively in the tumor biology field.
  • Glycoforms potentially associated with carcinogenesis, tumor progression and cancer metastasis have been identified.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / metabolism. Drug Resistance, Neoplasm. Glycosyltransferases / metabolism. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Polysaccharides / metabolism
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Carbohydrate Sequence. Down-Regulation. Drug Tolerance. Epirubicin / pharmacology. Fucosyltransferases / metabolism. Glycosylation. Humans. Mitoxantrone / pharmacology. N-Acetylglucosaminyltransferases / metabolism. Oligosaccharides, Branched-Chain / chemistry. Oligosaccharides, Branched-Chain / metabolism. Tumor Cells, Cultured. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Membr Biol. 2000 Feb 1;173(3):203-14 [10667916.001]
  • [Cites] Mol Cancer. 2006;5:75 [17187689.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26733-40 [11986321.001]
  • [Cites] J Biol Chem. 2003 Jan 31;278(5):3466-73 [12427744.001]
  • [Cites] Mol Cancer Ther. 2003 Feb;2(2):199-205 [12589037.001]
  • [Cites] Mol Cancer Ther. 2003 Nov;2(11):1207-14 [14617794.001]
  • [Cites] Gan. 1975 Aug;66(4):385-92 [52570.001]
  • [Cites] Biochem Biophys Res Commun. 1978 Nov 14;85(1):257-63 [743278.001]
  • [Cites] J Biol Chem. 1983 Dec 10;258(23):14126-9 [6643471.001]
  • [Cites] Science. 1987 May 1;236(4801):582-5 [2953071.001]
  • [Cites] Anal Biochem. 1988 May 15;171(1):73-90 [3407923.001]
  • [Cites] J Biol Chem. 1989 Feb 15;264(5):2415-23 [2536709.001]
  • [Cites] J Biochem. 1989 Apr;105(4):547-55 [2503497.001]
  • [Cites] Glycobiology. 1993 Apr;3(2):97-130 [8490246.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2970-5 [7686446.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Oct 29;196(2):714-20 [8240348.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):670-5 [7710927.001]
  • [Cites] Arch Biochem Biophys. 1995 Aug 1;321(1):51-60 [7639535.001]
  • [Cites] J Cancer Res Clin Oncol. 1997;123(5):296-9 [9201254.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3949-53 [10463590.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):256-62 [15688387.001]
  • [Cites] Biochemistry. 2005 Apr 12;44(14):5420-9 [15807535.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Oct;56(4):344-50 [15875186.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15791-6 [16236725.001]
  • [Cites] J Immunol Methods. 2005 Nov 30;306(1-2):93-103 [16236307.001]
  • [Cites] J Biol Chem. 2006 Feb 3;281(5):2572-7 [16316986.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 10;341(2):478-82 [16434023.001]
  • [Cites] J Proteome Res. 2006 Feb;5(2):308-15 [16457596.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2803-8 [16385567.001]
  • [Cites] Anticancer Res. 2006 Mar-Apr;26(2A):885-8 [16619483.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2506-11 [16638859.001]
  • [Cites] J Biol Chem. 2006 Oct 6;281(40):29797-806 [16899455.001]
  • [Cites] Mol Cancer. 2006;5:74 [17173689.001]
  • [Cites] J Cell Biochem. 2000 Sep 7;79(3):370-85 [10972975.001]
  • (PMID = 17488527.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Oligosaccharides, Branched-Chain; 0 / Polysaccharides; 3Z8479ZZ5X / Epirubicin; BZ114NVM5P / Mitoxantrone; EC 2.4.- / Glycosyltransferases; EC 2.4.1.- / Fucosyltransferases; EC 2.4.1.- / N-Acetylglucosaminyltransferases; EC 2.4.1.150 / N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase
  • [Other-IDs] NLM/ PMC1878497
  •  go-up   go-down


50. Hobson HP, Brown MR, Rogers KS: Surgery of metastatic anal sac adenocarcinoma in five dogs. Vet Surg; 2006 Apr;35(3):267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of metastatic anal sac adenocarcinoma in five dogs.
  • OBJECTIVE: To identify survival and morbidity information after surgery for metastases from apocrine gland anal sac adenocarcinomas (AGACA).
  • CONCLUSION: Dogs with anal sac adenocarcinoma metastases to the iliac lymph nodes can experience long-term survival after surgical excision of the metastatic lesion.
  • CLINICAL RELEVANCE: Lymphadenectomy may afford long-term survival to patients with metastatic anal sac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / veterinary. Anal Gland Neoplasms / surgery. Anal Sacs. Dog Diseases / surgery
  • [MeSH-minor] Animals. Dogs. Female. Lymph Node Excision / veterinary. Lymphatic Metastasis. Male. Neoplasm Metastasis. Postoperative Complications / veterinary. Records as Topic / veterinary. Retrospective Studies. Survival Analysis. Texas / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Compend Contin Educ Vet. 2008 Feb;30(2):69, 72 [23713167.001]
  • (PMID = 16635006.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Oliveira PA, Adega F, Palmeira CA, Chaves RM, Colaço AA, Guedes-Pinto H, De la Cruz P LF, Lopes CA: DNA study of bladder papillary tumours chemically induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in Fisher rats. Int J Exp Pathol; 2007 Feb;88(1):39-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The animals exposed to BBN were killed at a rate of two per week, with the bladder being collected under aseptic conditions and those tumours with exophytic growth removed.
  • In two rats part of the tumour pieces was stipulated for culturing.
  • In addition, the occurrence of marker chromosomes seems to be related to the aggressiveness of the tumour.
  • [MeSH-major] Carcinoma, Papillary / genetics. Chromosome Aberrations. DNA, Neoplasm / analysis. Urinary Bladder Neoplasms / genetics
  • [MeSH-minor] Animals. Butylhydroxybutylnitrosamine. Carcinogens. Cytogenetics. Female. Neoplasms, Experimental. Rats. Rats, Inbred F344. Urothelium

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2001 Apr 26;344(17):1270-8 [11320386.001]
  • [Cites] Acta Pathol Jpn. 1982 Mar;32(2):243-50 [7090816.001]
  • [Cites] Hum Pathol. 1993 Feb;24(2):173-81 [8381766.001]
  • [Cites] IARC Sci Publ. 1994;(111):383-406 [8082914.001]
  • [Cites] Hum Pathol. 1995 Jan;26(1):3-11 [7821913.001]
  • [Cites] Diagn Cytopathol. 1995 Oct;13(3):214-23; discussion 224 [8575280.001]
  • [Cites] Semin Urol Oncol. 1996 Feb;14(1 Suppl 1):1-9 [8727804.001]
  • [Cites] Cytometry. 1997 Jun 1;28(2):176-80 [9181309.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):762-8 [9267817.001]
  • [Cites] J Urol. 1998 Dec;160(6 Pt 1):1971-4 [9817302.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Cancer Detect Prev. 1999;23(5):401-7 [10468892.001]
  • [Cites] Genetica. 2004 Jul;121(3):315-25 [15521430.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7607-12 [15569992.001]
  • [Cites] Urol Oncol. 2004 Nov-Dec;22(6):443-7 [15610858.001]
  • [Cites] Arch Biochem Biophys. 2005 Mar 1;435(1):56-64 [15680907.001]
  • [Cites] Int J Cancer. 2005 Jul 1;115(4):591-8 [15704106.001]
  • [Cites] Oncol Rep. 2006 Jan;15(1):213-9 [16328058.001]
  • [Cites] Cell Oncol. 2005;27(5-6):293-318 [16373963.001]
  • [Cites] EXS. 2006;(96):49-64 [16383014.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):609-16 [16471324.001]
  • [Cites] J Hered. 2006 Mar-Apr;97(2):114-8 [16469867.001]
  • [Cites] Dtsch Med Wochenschr. 2006 Aug 4;131(31-32):1747-53 [16868879.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):2995-3004 [16886626.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 4;94(17):1320-9 [12208897.001]
  • [Cites] Mutat Res. 2002 Nov 26;521(1-2):81-9 [12438006.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Mar;149(2):107-13 [15036885.001]
  • [Cites] IUBMB Life. 2004 Feb;56(2):65-81 [15085930.001]
  • [Cites] Int J Oncol. 2004 Oct;25(4):893-8 [15375537.001]
  • [Cites] Mol Carcinog. 2004 Oct;41(2):69-76 [15378645.001]
  • [Cites] J Korean Med Sci. 2004 Oct;19(5):682-7 [15483344.001]
  • [Cites] Curr Top Pathol. 1979;67:145-232 [456044.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):927-32 [7459879.001]
  • [Cites] J Natl Cancer Inst. 1989 Mar 1;81(5):361-7 [2915372.001]
  • (PMID = 17244337.001).
  • [ISSN] 0959-9673
  • [Journal-full-title] International journal of experimental pathology
  • [ISO-abbreviation] Int J Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA, Neoplasm; 3817-11-6 / Butylhydroxybutylnitrosamine
  • [Other-IDs] NLM/ PMC2517286
  •  go-up   go-down


52. Prinetti A, Millimaggi D, D'Ascenzo S, Clarkson M, Bettiga A, Chigorno V, Sonnino S, Pavan A, Dolo V: Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells. Biochem J; 2006 Apr 15;395(2):311-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Ceramides / biosynthesis. Drug Resistance, Neoplasm. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sphingolipids / chemistry. Sphingolipids / metabolism
  • [MeSH-minor] Animals. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Cattle. Cell Line, Tumor. Female. Gangliosides / metabolism. Humans. Paclitaxel / pharmacology. Rats. Sphingomyelin Phosphodiesterase / antagonists & inhibitors. Tritium

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2003 Jul 31;548(1-3):28-32 [12885402.001]
  • [Cites] J Biol Chem. 2005 Jul 29;280(30):27879-87 [15946935.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):264-9 [14670935.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Mar;23(1):83-91 [15149155.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3593-8 [15150117.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4592-602 [15256490.001]
  • [Cites] Adv Exp Med Biol. 1980;125:11 [7361610.001]
  • [Cites] Anal Biochem. 1983 Jan;128(1):104-14 [6846788.001]
  • [Cites] J Biol Chem. 1994 Feb 4;269(5):3125-8 [8106344.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;35(4):297-303 [7828272.001]
  • [Cites] Drugs. 1994 Nov;48(5):794-847 [7530632.001]
  • [Cites] Cell. 1995 Aug 11;82(3):405-14 [7634330.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12646-54 [8647877.001]
  • [Cites] Glycoconj J. 1996 Jun;13(3):347-52 [8781964.001]
  • [Cites] Leukemia. 1997 Feb;11(2):253-7 [9009089.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):6918-26 [9054379.001]
  • [Cites] Oncol Res. 1997;9(3):129-38 [9220498.001]
  • [Cites] Am J Clin Oncol. 1997 Oct;20(5):522-6 [9345342.001]
  • [Cites] Glycobiology. 1998 Oct;8(10):xi-xix [9840984.001]
  • [Cites] J Biol Chem. 1999 Jan 8;274(2):1140-6 [9873062.001]
  • [Cites] J Biol Chem. 2000 Apr 21;275(16):11658-65 [10766784.001]
  • [Cites] Glia. 2000 Nov;32(2):137-45 [11008213.001]
  • [Cites] FASEB J. 2001 Mar;15(3):719-30 [11259390.001]
  • [Cites] Int J Cancer. 2001 Jul 1;93(1):131-8 [11391632.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21136-45 [11264283.001]
  • [Cites] Bioorg Med Chem. 2001 Nov;9(11):2901-4 [11597471.001]
  • [Cites] Subcell Biochem. 2002;36:187-205 [12037981.001]
  • [Cites] FASEB J. 2002 Jul;16(9):1111-3 [12039850.001]
  • [Cites] FEBS Lett. 2002 Oct 23;530(1-3):9-16 [12387858.001]
  • [Cites] J Exp Med. 2002 Dec 16;196(12):1535-41 [12486096.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5574-83 [12486134.001]
  • [Cites] J Neurosci Res. 2003 Apr 1;72(1):65-75 [12645080.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2002 May;2(3):387-401 [12678739.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2003 Jul;3(4):263-70 [12769772.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2282-96 [10090938.001]
  • [Cites] J Biol Chem. 1999 Jul 9;274(28):19792-8 [10391922.001]
  • [Cites] Oncogene. 2003 Oct 13;22(45):7070-7 [14557812.001]
  • (PMID = 16356169.001).
  • [ISSN] 1470-8728
  • [Journal-full-title] The Biochemical journal
  • [ISO-abbreviation] Biochem. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Ceramides; 0 / Gangliosides; 0 / Sphingolipids; 10028-17-8 / Tritium; EC 3.1.4.12 / Sphingomyelin Phosphodiesterase; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC1422777
  •  go-up   go-down


53. Crambert G, Li C, Claeys D, Geering K: FXYD3 (Mat-8), a new regulator of Na,K-ATPase. Mol Biol Cell; 2005 May;16(5):2363-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Finally, FXYD3 decreases both the apparent affinity for Na+ and K+ of Na,K-ATPase.
  • [MeSH-major] Membrane Proteins / metabolism. Neoplasm Proteins / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1991 Jun 15;266(17):11126-30 [1710217.001]
  • [Cites] Anal Biochem. 1989 Jul;180(1):147-51 [2530914.001]
  • [Cites] J Cell Biol. 1993 Dec;123(6 Pt 2):1751-9 [8276895.001]
  • [Cites] J Gen Physiol. 1994 Apr;103(4):605-23 [8057080.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):924-33 [7926482.001]
  • [Cites] Oncogene. 1994 Dec;9(12):3417-26 [7970700.001]
  • [Cites] J Biol Chem. 1995 Feb 3;270(5):2176-82 [7836447.001]
  • [Cites] J Cell Biol. 1996 Jun;133(6):1193-204 [8682858.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9606-11 [8790377.001]
  • [Cites] EMBO J. 1997 Jul 16;16(14):4250-60 [9250668.001]
  • [Cites] J Biol Chem. 1998 Nov 13;273(46):30826-35 [9804861.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33183-5 [10559186.001]
  • [Cites] J Biol Chem. 2000 Jan 21;275(3):1976-86 [10636900.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C541-66 [10942705.001]
  • [Cites] Genomics. 2000 Aug 15;68(1):41-56 [10950925.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):29011-22 [10887183.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):345-418 [11152761.001]
  • [Cites] EMBO J. 2001 Apr 2;20(7):1573-82 [11285222.001]
  • [Cites] J Biol Chem. 2001 Jun 8;276(23):20370-8 [11278761.001]
  • [Cites] EMBO J. 2001 Aug 1;20(15):3993-4002 [11483503.001]
  • [Cites] EMBO J. 2002 Jul 1;21(13):3264-73 [12093728.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11476-81 [12169672.001]
  • [Cites] Am J Physiol Renal Physiol. 2002 Oct;283(4):F607-15 [12217851.001]
  • [Cites] Sci STKE. 2003 Jan 21;2003(166):RE1 [12538882.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):18738-43 [12626497.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4602-6 [12907638.001]
  • [Cites] J Biol Chem. 2003 Oct 17;278(42):40437-41 [12907667.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):97-105 [14654946.001]
  • [Cites] J Mol Biol. 2004 Jul 16;340(4):783-95 [15223320.001]
  • [Cites] J Biol Chem. 2004 Jul 16;279(29):30888-95 [15133029.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):38895-902 [15234969.001]
  • [Cites] Biochemistry. 1981 Nov 10;20(23):6684-91 [6272846.001]
  • [Cites] J Mol Biol. 1984 Feb 25;173(2):243-51 [6423828.001]
  • [Cites] Nucleic Acids Res. 1984 Sep 25;12(18):7035-56 [6091052.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5798-801 [8449946.001]
  • (PMID = 15743908.001).
  • [ISSN] 1059-1524
  • [Journal-full-title] Molecular biology of the cell
  • [ISO-abbreviation] Mol. Biol. Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fxyd3 protein, mouse; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / Protein Sorting Signals; 0 / Recombinant Proteins; EC 3.6.3.10 / H(+)-K(+)-Exchanging ATPase; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase
  • [Other-IDs] NLM/ PMC1087241
  •  go-up   go-down


54. Aizawa J, Sakayama K, Kamei S, Kidani T, Yamamoto H, Norimatsu Y, Masuno H: Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8. BMC Cancer; 2010;10:51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of troglitazone on tumor growth and pulmonary metastasis development of the mouse osteosarcoma cell line LM8.
  • BACKGROUND: Osteosarcoma often develops micrometastases in the lung prior to diagnosis, causing a fatal outcome.
  • The effects of oral administration of either TGZ (TGZ group) or ethanol (control group) on the growth of primary tumor and the development of pulmonary metastasis were examined in nude mice implanted with LM8 cells on their backs.
  • The expression and activity of matrix metalloproteinase 2 (MMP-2) within the tumor were determined by immunohistochemistry and zymography.
  • The microvessel density (MVD) within the tumor was determined by immunohistochemistry for CD34.
  • The primary tumor mass was smaller in the TGZ group than in the control group.
  • The TGZ group had less metastatic tumors in the lung compared with the control group.
  • The expression and activity of MMP-2 within the tumor of the TGZ group were lower than those of the control group.
  • The MVD within the tumor of the TGZ group was lower than that of the control group.
  • Treatment of tumor-bearing mice with TGZ decreases the expression and activity of MMP-2 within the tumor, and inhibits primary tumor growth and pulmonary metastasis development.
  • [MeSH-major] Chromans / therapeutic use. Lung Neoplasms / drug therapy. Osteosarcoma / pathology. Thiazolidinediones / therapeutic use
  • [MeSH-minor] Animals. Antigens, CD34 / biosynthesis. Cell Line, Tumor. Humans. Hypoglycemic Agents / therapeutic use. Male. Matrix Metalloproteinase 2 / biosynthesis. Mice. Mice, Inbred BALB C. Mice, Nude. Microcirculation. Neoplasm Metastasis. Neoplasm Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Biol. 1999 Oct 21;9(20):R776-8 [10531025.001]
  • [Cites] Int J Cancer. 2009 Dec 1;125(11):2576-85 [19551863.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Invest. 2001;19(3):292-315 [11338887.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7647-53 [11606407.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 25;290(3):1123-7 [11798192.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1466-75 [11920503.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):344-51 [11920584.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1288-94 [12006550.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):1-9 [12538445.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2172-8 [12727836.001]
  • [Cites] Toxicol Sci. 2003 Oct;75(2):314-20 [12883076.001]
  • [Cites] J Orthop Res. 2004 Nov;22(6):1168-74 [15475193.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7022-30 [15501982.001]
  • [Cites] Anal Biochem. 1971 Jan;39(1):197-201 [5544593.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 May;82(10):3262-6 [2860667.001]
  • [Cites] Arch Pathol Lab Med. 1987 Sep;111(9):841-5 [2888448.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cell. 1996 Nov 1;87(3):377-89 [8898192.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:335-63 [8970730.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(14):2474-84 [9059336.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):418-22 [9579581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8806-11 [9671760.001]
  • [Cites] Diabet Med. 1999 Mar;16(3):179-92 [10227562.001]
  • [Cites] Cancer Chemother Pharmacol. 1999;43 Suppl:S42-51 [10357558.001]
  • [Cites] Br J Pharmacol. 2004 Dec;143(8):933-7 [15533890.001]
  • [Cites] Toxicol Sci. 2005 Apr;84(2):319-27 [15659569.001]
  • [Cites] Oncol Rep. 2005 Oct;14(4):847-52 [16142341.001]
  • [Cites] BMC Cancer. 2006;6:53 [16519808.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):702-13 [17096328.001]
  • [Cites] BMC Cancer. 2007;7:216 [18021457.001]
  • [Cites] BMC Cancer. 2008;8:47 [18261208.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:69 [19014499.001]
  • [Cites] Cancer Sci. 2009 Apr;100(4):770-7 [19469020.001]
  • [Cites] J Orthop Res. 2009 Jul;27(7):909-15 [19105229.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):572-7 [10690541.001]
  • (PMID = 20170548.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Chromans; 0 / Hypoglycemic Agents; 0 / Thiazolidinediones; EC 3.4.24.24 / Matrix Metalloproteinase 2; I66ZZ0ZN0E / troglitazone
  • [Other-IDs] NLM/ PMC2838820
  •  go-up   go-down


55. Chang CK, Hung WC, Chang HC: The Kazal motifs of RECK protein inhibit MMP-9 secretion and activity and reduce metastasis of lung cancer cells in vitro and in vivo. J Cell Mol Med; 2008 Dec;12(6B):2781-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECK is a membrane-anchored glycoprotein which may negatively regulate matrix metalloproteinase (MMP) activity to suppress tumor invasion and metastasis.
  • Moreover, K23 reduced metastatic tumor growth in lungs of nude mice.
  • [MeSH-major] Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 9 / secretion. Membrane Glycoproteins / chemistry. Membrane Glycoproteins / metabolism
  • [MeSH-minor] Amino Acid Motifs. Animals. Cell Line, Tumor. Cell Movement. GPI-Linked Proteins. Humans. Matrix Metalloproteinase Inhibitors. Mice. Neoplasm Invasiveness. Neoplasm Metastasis. Peptides / metabolism. Protein Binding. Sequence Deletion. Structure-Activity Relationship

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194466.001).
  • [ISSN] 1582-1838
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Matrix Metalloproteinase Inhibitors; 0 / Membrane Glycoproteins; 0 / Peptides; 0 / RECK protein, human; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC3828891
  •  go-up   go-down


56. Min JJ, Kim HJ, Park JH, Moon S, Jeong JH, Hong YJ, Cho KO, Nam JH, Kim N, Park YK, Bom HS, Rhee JH, Choy HE: Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol; 2008 Jan-Feb;10(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli.
  • PURPOSE: A number of bacteria types are known to preferentially grow in tumors.
  • We have taken advantage of this phenomenon to target luciferase-expressing Escherichia coli to tumors and metastases in mouse models to image them noninvasively.
  • METHODS AND RESULTS: After intravenous injection of pLux-expressing E. coli (10(8) CFU), bioluminescence signals from the bacteria were detected exclusively in tumor tissue after 24 hours.
  • The balanced-lethal host-vector system using the gene encoding aspartate beta-semialdehyde dehydrogenase (asd) enabled stable maintenance of the pLux in the tumor-targeting E. coli.
  • This phenomenon of selective tumor targeting and proliferation of E. coli was observed in a diverse range of tumors implanted in nude mice.
  • More importantly, E. coli was capable of targeting both primary tumors and metastases, enabling them to be imaged noninvasively in both nude and immunocompetent mice.
  • CONCLUSIONS: Our results suggest the potential clinical use of this technology for tumor targeting.
  • [MeSH-major] Escherichia coli / metabolism. Imaging, Three-Dimensional / methods. Light. Neoplasms / diagnosis. Neoplasms / microbiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Luciferases / metabolism. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Metastasis. Photons. Rats. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Bioanal Chem. 2003 Nov;377(6):964-72 [12879198.001]
  • [Cites] Med Klin. 1967 Feb 3;62(5):189-93 [5590189.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1453-62 [9278503.001]
  • [Cites] Gene Ther. 1997 Aug;4(8):791-6 [9338007.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1363-80 [10751361.001]
  • [Cites] Gene. 1990 Sep 28;94(1):29-35 [2227450.001]
  • [Cites] J Clin Invest. 2000 Apr;105(8):1027-30 [10772643.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7647-52 [16885365.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2662-5 [8653713.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4537-44 [9377566.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14 ):3683-8 [10919633.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):313-20 [14990953.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1605-6 [10430057.001]
  • [Cites] Lancet Oncol. 2003 Sep;4(9):548-56 [12965276.001]
  • [Cites] Immunol Invest. 1989 Jan-May;18(1-4):583-96 [2659521.001]
  • [Cites] Nat Biotechnol. 1999 Jan;17(1):37-41 [9920266.001]
  • [Cites] Gastroenterology. 1992 Feb;102(2):474-85 [1732118.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):14748-50 [11752416.001]
  • [Cites] Cancer Res. 1992 Mar 15;52(6):1399-405 [1540948.001]
  • [Cites] Invest New Drugs. 1999;17(4):343-59 [10759402.001]
  • [Cites] Eur J Biochem. 1991 Oct 1;201(1):161-7 [1915359.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):755-60 [15644448.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15155-60 [11724950.001]
  • [Cites] Cancer Res. 1964 Feb;24:222-33 [14115688.001]
  • [Cites] Methods Mol Med. 2004;90:47-60 [14657558.001]
  • [Cites] Gene Ther. 1996 Feb;3(2):173-8 [8867865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10170-4 [17548809.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5 [10829079.001]
  • [Cites] Infect Immun. 2002 Apr;70(4):1739-49 [11895935.001]
  • (PMID = 17994265.001).
  • [ISSN] 1536-1632
  • [Journal-full-title] Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • [ISO-abbreviation] Mol Imaging Biol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.13.12.- / Luciferases
  •  go-up   go-down


57. Ranger-Moore J, Frank D, Lance P, Alberts D, Yozwiak M, Bartels HG, Einspahr J, Bartels PH: Karyometry in rectal mucosa of patients with previous colorectal adenomas. Anal Quant Cytol Histol; 2005 Jun;27(3):134-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 57 cases recurrent polyps occurred (R cases); in 72 cases no recurrent disease was found at the end of the study (NR cases).
  • RESULTS: The differences in karyometricfeature values for nuclei from biopsies of cases with recurrent or nonrecurrent disease were very small and not notably expressed in the majority of nuclei.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121634.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-41108; United States / NCI NIH HHS / CA / CA-53877-09
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cholagogues and Choleretics; 724L30Y2QR / Ursodeoxycholic Acid
  •  go-up   go-down


58. Elwanis MA, Maximous DW, Elsayed MI, Mikhail NN: Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial. World J Surg Oncol; 2009;7:52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sphincter preserving surgery for cancer of the lower rectum needs a long-course of neoadjuvant treatments to reduce tumor volume, to induce down-staging that increases circumferential resection margin, and to facilitate surgery.
  • AIM: To evaluate the rate of anal sphincter preservation in low lying, resectable, locally advanced rectal cancer and the resectability rate in unresectable cases after neoadjuvent chemoradiation by oral Capecitabine.
  • PATIENTS AND METHODS: This trial included 43 patients with low lying (4-7 cm from anal verge) locally advanced rectal cancer, of which 33 were resectable.
  • The majority (75%) were of clinical T3 disease.
  • CONCLUSION: In patients with low lying, locally advanced rectal cancer, preoperative chemoradiation using oral capecitabine 825 mg/m2, twice a day on radiotherapy days, was tolerable and effective in downstaging and resulted in 46.5% anal sphincter preservation rate.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Capecitabine. Combined Modality Therapy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2948-53 [10537364.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(4):291-7 [10755317.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3471-7 [18846402.001]
  • [Cites] Strahlenther Onkol. 2008 Sep;184(9):450-6 [19016023.001]
  • [Cites] Oncology. 2007;73(3-4):169-76 [18418009.001]
  • [Cites] Neth J Med. 2008 Feb;66(2):71-6 [18292610.001]
  • [Cites] Am J Clin Oncol. 2007 Aug;30(4):340-5 [17762432.001]
  • [Cites] Croat Med J. 2006 Oct;47(5):693-700 [17042060.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):762-71 [17011451.001]
  • [Cites] Ann Ital Chir. 2006 Jan-Feb;77(1):41-6 [16910358.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):361-71 [16500912.001]
  • [Cites] Ann Oncol. 2006 Feb;17(2):246-51 [16282246.001]
  • [Cites] J Gastrointest Surg. 2005 Dec;9(9):1222-7; discussion 1227-8 [16332477.001]
  • [Cites] Radiother Oncol. 2005 Sep;76(3):241-50 [16165238.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):346-53 [15913913.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):465-9 [15729069.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2025-31 [15657650.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):319-24 [9788410.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):281-7 [9069298.001]
  • [Cites] J Am Coll Surg. 1995 Oct;181(4):335-46 [7551328.001]
  • [Cites] Radiother Oncol. 2004 Jul;72(1):15-24 [15236870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):654-60 [12377315.001]
  • [Cites] Lancet Oncol. 2002 Jul;3(7):415-24 [12142171.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):874-82 [12003422.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):973-6 [11978522.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1039-45 [11583178.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • (PMID = 19508705.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2699338
  •  go-up   go-down


59. Liang S, Singh M, Gam LH: The differential expression of aqueous soluble proteins in breast normal and cancerous tissues in relation to stage and grade of patients. J Biomed Biotechnol; 2010;2010:516469
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patients were divided into different cohorts according to tumour stage and grade.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Proteomics / methods